Download Danish Cancer Society Annual Report 2012

Danish Cancer Society
Annual Report 2012
Danish Cancer Society | Annual Report 2012
In 2012, 14-year-old Maria Eriksen
from Northern Jutland lost her father
to cancer. Maria does not attend a
grief-therapy group, but has received family counselling at the Danish
Cancer Society in Aalborg together
with her brother, Daniel, and her
mother, Hanne Eriksen. Maria Eriksen
is pictured at the Copenhagen Opera
House – waiting to present HRH
Crown Princess Mary with a bouquet
of flowers on the occasion of World
Cancer Day.
2
Vision and Goals
The Danish Cancer Society’s vision is
a life without cancer
This vision is realised by
• preventing the occurrence of cancer;
• offering the possibility of a cure;
• helping those afflicted.
With its widespread popular support and
with the expertise and skills achieved through
research, patient support, prevention and
information activities, the Danish Cancer
Society aims to:
• monitor and safeguard patient rights;
• identify problems and obstacles;
• offer professional and political advice;
• define goals and possible solutions;
• promote and lead the developments and
activities required to reach these goals;
• involve relevant parties;
• monitor and record results.
The Danish Cancer Society works to improve the
situation of cancer patients and optimise every
aspect of the cancer pathway.
The cancer pathway includes all initiatives and
offers: from research and prevention, through
therapy and care, to rehabilitation and palliation.
This goal applies to the Danish Cancer Society’s
own activities as well as the efforts for which
the public sector is responsible.
3
Icy dip
Niels Jessen of Farum was
diagnosed with head and
neck cancer ten years ago.
The treatment devastated
him, and he still suffers from
the same sequelae as when
he completed his treatment,
such as disabling fatigue. “I’m
not sure if an icy dip relieves
my fatigue, but it sure cures
winter depression,” he says.
Niels Jessen is chairman of
the Network for patients with
cancer of the throat and oral
cavity.
Contents
Management’s Report
Cancer Research
Prevention
Patient Support
Achievements in 2012
Focal Points in 2013
Finances
Organisation, Management and Committees
Research Grants
Patients’ Associations
Cancer Counselling Centres
Organisation
Editors:
Kurt Damsgaard (editor-in-chief),
communications manager
Jytte Dreier, editor
Design:
Dorte Kayser, Datagraf Communications
Printed by: Datagraf Communications
Translation: ad Astra Translatører
Photos: Tomas Bertelsen
ISSN: 0903-6504
4
6
8
20
26
32
34
36
66
68
80
81
83
Danish Cancer Society | Annual Report 2012
Foreword
RESEARCH PAVES THE WAY
In 2012, the Danish Cancer Society’s research was
once again rated at the top of the world’s elite. The
Danish Cancer Society Research Center is ranked
an undisputed number 1 in the Nordic region and
number 22 in Europe out of more than 3,000 of the
world’s leading universities and research institutions.
We are proud of this - and of the great results from
research projects supported by the Danish Cancer
Society at a number of hospitals and universities.
But we do not intend to rest on our laurels. We are
continuously striving to become even better at conducting trail-blazing research which may be quickly
deployed for the benefit of cancer patients.
A major challenge in our research remains to
identify the causes of cancer, which will allow us
to conduct research into improved and increasingly
precise therapies while at the same time becoming
far better at preventing cancer.
Living spaces
The Danish Cancer Society steps in when cancer
patients and their relatives feel that the system lets
them down. And we step in when people need help
and support.
For more than 25 years, the Danish Cancer Society
has offered free support and counselling to everyone experiencing cancer close up. We will, of course,
continue to do this. But we want to be able to help
far more cancer patients, relatives and the bereaved.
Consequently, in collaboration with Realdania we are
building seven new cancer counselling centres. We
call them ‘living spaces’ (“Livsrum”).
The counselling centres will be built in close proximity to the oncology wards in Aalborg, Herning,
Vejle, Odense, Roskilde, Næstved and Herlev, which
provides cancer patients with easy access to see
a counsellor, meet with other people in the same
situation, take part in activities or simply relax over
a cup of coffee before the next hospital examination. There will be a wide range of offers for users
at each of the cancer counselling centres – offers
which have been and will be developed according to
users needs and desires.
A responsible healthcare system
The new cancer counselling centres cannot accomplish
the task alone. There is consequently a great need for
the help and support provided to cancer patients and
relatives by volunteers in the local units. Among the
offers in high demand is a café for cancer patients in
conjunction with a municipal training programme.
Our goal is that cancer should not be fatal but a
disease you can live with.
Leif Vestergaard
Pedersen,
managing director
One of our primary challenges is to make sure that
we have a responsible healthcare system where
cancer patients and their relatives get involved in
their own cancer pathway. We also strive to achieve
quality at the highest international level throughout the cancer pathway – from early diagnosis and
treatment to counselling, rehabilitation or palliative
treatment for incurable patients. In addition, we
contribute knowledge and research to the healthcare system.
The Annual Report gives you a glimpse of what
the Danish Cancer Society has been working on in
2012, and outlines what we will do in 2013. Enjoy
your reading!
Changing norms and culture
“Yes to a ban on smoking during working hours”,
“Turn down the sun” and “The Smoking Act should
also apply to e-cigarettes.” At the Danish Cancer
Society, we attack the root of the problem and
say what others are afraid to say. We must try to
influence the norms and culture in society around us
whenever there is scientific evidence to do so. This
is our duty.
A new focus area, which is sure to cause controversy among the Danish population, is Youths &
Alcohol. We need to change the drinking culture and
habits of young people. One way of doing this is by
means of a campaign which will be launched in the
course of 2013.
If you scan the QR code below, you can see a film with Leif Vestergaard
Pedersen, managing director, talking about the Society’s work (in Danish).
What to do:
•D
ownload and install a free app (such as Scanlife) on your smartphone and scan the code.
•O
r send a text message with the word ’scan’ to
1220. Follow the instructions and scan the code.
Please note that when using 2D codes and sending
text messages, your carrier’s standard messaging
and data charges apply and are charged via your phone bill.
5
Danish Cancer Society | Annual Report 2012
MANAGEMENT’S REPORT
4,400 cancer patients participated in the Danish Cancer
Society’s nationwide survey in 2012, which focused on
cancer patients’ needs and experiences during and after
treatment. The overall result of the survey is that, fortunately, quite a lot of patients lead a good life after the
completion of cancer treatment.
However, many people find it difficult to regain their
footing, and they lack information and support from their
municipalities and general practitioners to help them adjust to their new everyday life. The survey showed that
one in five had been admitted through the emergency
ward during their treatment pathway, and one in four
experienced complications relating to surgery. The survey
has further revealed that almost half of the participants
needed help to handle physical problems, but that only
one-third received the necessary support. Forty-five
percent needed help to deal with emotional problems.
Also when it comes to the need for home nursing care
and domestic help, many respondents feel that the municipality fails to live up to its responsibility.
The survey, which is part of a recurring nationwide
charting of the current situation for cancer patients, was
launched by the Danish Cancer Society’s Central Board.
Its results provide valuable knowledge to the Danish
Cancer Society and will subsequently contribute to the
continued effort to give Danish cancer patients a feeling
of consistency and supreme quality during the entire
cancer pathway.
Acute cancer
The Danish Cancer Society has long desired that the
Danish regions would report waiting times for all cancer
6
patients. Therefore, we are very pleased that, as of
February 2012, it became mandatory for the regions to
report waiting times for cancer packages. The figures will
be published for the first time in May 2013. The Danish
Cancer Society is keeping an eye on this, and will have
extra focus on ensuring that cancer patients are in fact
treated on time. Throughout the coming year, the Danish
Cancer Society will focus particularly on the waiting time
until making the diagnosis and on the waiting time for
examinations that are initiated before starting the cancer
therapy.
Act on Smoke-Free Environments
One of the main objectives of the Danish Cancer Society
is to prevent Danes from taking up smoking, as smoking
is the most frequent cause of cancer. The most recent
amendment of the Act on Smoke-Free Environments
bans smoking at primary and secondary schools and
other institutions for young people below the age of 18.
At Danish workplaces, smoking is no longer allowed in individual offices. Unfortunately, however, it is still allowed
in smoking cubicles.The Danish Cancer Society continues
its fight to ensure clean air for all.
Vaccination against cervical cancer
The Danish Cancer Society is working decisively to
achieve the highest vaccination rate in the world, and
in 2012, access to vaccination was backed by a large
campaign, ‘Wonder Life Friends’ (“Veninder for Vidunderlivet”), which encourages all Danish women born
between 1985 and 1992 to accept the offer of free
vaccination, which expires at the end of 2013. The Danish Cancer Society expects that the campaign will help to
reduce the number of deaths caused by cervical cancer
and reduce the number of conisations once the full effect
of the vaccine kicks in. Women are accepting the free
vaccine offer. At the end of 2012, 56% of the target
group had been vaccinated. Before the vaccine was offered for free, this figure was approx. 17%.
The ‘Beat Cancer’ campaign
In 2012, the Danish Cancer Society launched a new 'Beat
Cancer' fundraising campaign on TV2 in week 43. The
campaign raised an astounding DKK 100 million for the
Danish Cancer Society. With this kind of support from
the people of Denmark, the Danish Cancer Society hopes
that the 2013 campaign will be an even greater success.
And the goal is to reach even more Danes. The funds
raised during the campaign will be used for purposes
such as conducting research into early diagnosis and
improved diagnostics, research into rehabilitation for
cancer patients during and after treatment and supporting a rewarding life after cancer, as well as a colon-cancer
information campaign.
Dallund Rehabilitation Centre
For many years, the Danish Cancer Society has promoted
the inclusion of Dallund Rehabilitation Centre in the Danish Finance and Appropriation Act. And from 2013, our
efforts will bear fruit. The Dallund Rehabilitation Centre
is now part of a new research and development centre
based in the Region of Southern Denmark. The ‘new’
centre will consist of an R&D department and a communications and documentation department. The centre will
continue to conduct research which is aimed at providing
knowledge about and increasing rehabilitation offers for
the more than 230,000 Danes living with cancer.
Maximum duration of sickness benefits
Some cancer-afflicted sickness benefit recipients are not covered
by any of the current options for extending the sickness benefit
period, which means they lose their basic income in the midst
of a therapy whose outcome is uncertain. The Danish Cancer
Society is therefore working intensively on promoting a so-called
‘eighth extension rule’ which provides for an indefinite extension
of the sickness benefit period for the most severely ill patients.
Voluntary work
In October 2012, the volunteer portal, frivillig.dk, was launched,
marking a decisive step in efforts to strengthen voluntary work
for the Danish Cancer Society. We hope that the portal will
make it easier and more rewarding to be a volunteer. Volunteers
seem to have embraced the new site in any case. Almost 900
people created a profile during the first two months. Frivillig.
dk is extremely important because voluntary work is an essential prerequisite for much of the funding of the Danish Cancer
Society’s work.
The Society
In 2012, the Committee of Representatives decided to revise
the Danish Cancer Society’s Articles of Association. Local units
and regional committees contributed proposals and comments.
The revision of the Articles of Association must be finished in
2014 and presented to the Committee of Representatives for
approval.
2012 was also the year when the management launched a major
project of formulating new goals to replace the 2015 goals.
Based on the Danish Cancer Society’s foundation, five strategic
goals for the cancer cause and the Society’s work towards 2020
are being developed.
7
Danish Cancer Society | Annual Report 2012
The Danish Cancer Society has built
up a large, unique biobank containing samples of blood, urine and
fat tissue from more than 57,000
Danish men and women. The large
biobank is valuable to people like
Anja Olsen, senior researcher from
the Danish Cancer Society Research
Center, who conducts research into
correlations between dietary habits,
lifestyle and cancer.
8
cancer research
The world-class research produced by the Danish Cancer Society
needs to be maintained and further developed. The Society spends
approx. DKK 250 million on research every year.
Research grants from the
Danish Cancer Society 2002 – 2012
DKK million
300
250
200
150
100
50
0
2002
2004
2006
2008
2010
2012
9
Danish Cancer Society | Annual Report 2012
THE DANISH CANCER SOCIETY RESEARCH CENTer
Almost half of the funding received by the Danish Cancer Society is used for research. This
research aims to pave the way for reducing the cancer rate, increasing the survival rate and
ensuring that survivors lead more rewarding lives after cancer. The Danish Cancer Society
conducts its own research and at the same time supports cancer research at hospitals and
universities throughout Denmark.
On 1 January 2012, all researchers were gathered under
one umbrella at the Danish Cancer Society Research
Center. This merger of biological and epidemiological
research aims to improve the collaboration between
these two different research areas. New knowledge from
biological research may be applied by epidemiologists to
generate new results – and vice versa.
This implies an important organisational change towards
fewer but larger research groups to provide better prospects for researchers to collaborate more closely across
research disciplines.
The goal is:
• to
procure new knowledge about the causes of cancer,
thus making prevention of cancer more efficient;
• t o develop examination techniques for early detection
to ensure that the disease is identified at a curable
stage;
• t o find gentler alternatives to chemotherapy and
radiation therapy for patients who still require intensive
cancer treatment; and
• t o measure the scope of harmful long-term sequelae
of cancer treatment on patients’ physical and mental
health, so that such effects can be prevented, treated
or relieved in the future.
10
In four out of ten cases of cancer, the cause is known,
and these causes include tobacco, sunlight, alcohol,
radioactive radiation and HPV infection. In order to become better at preventing cancer, however, a targeted
research effort is required. Even though treatment has
improved in recent decades, many patients still die from
cancer. The Danish Cancer Society Research Center
works to develop methods which can predict the effect
of a treatment on individual patients, thus enabling doctors to choose the ‘right treatment for the right patient
at the right time’.
In addition, the researchers focus on mental and social
conditions and how these affect how patients cope with
cancer.
The research carried out at the Centre also ensures that
the Danish Cancer Society’s scientific decisions and
recommendations for politicians, healthcare professionals and cancer patients are always in line with the latest
knowledge.
In 2012, the Centre employed more than 160 researchers and specialists representing 20 nationalities, and
attracted 60 international visiting researchers.
Eight years of world-class research
Since 2004, the Danish Cancer Society’s research
organisation has been rated among the best in the
world. In 2012 the Danish Cancer Society was once
again ranked as the undisputed best institution in the
Nordic region and 22nd in Europe by the international
Scimago Institutions Rankings, which annually ranks
the best research institutions in the world. Scimago
evaluated more than 3,000 research institutions and
universities, and the research conducted by the Danish
Cancer Society was consistently among the top 100
in the world.
The Top 10 of Research
“Over the last eight years, our cancer research has
succeeded in maintaining a top position in the international ranking of research, which, in the world of
research, is considered the ‘international scorecard for
good research’. Yet even though our research scores
high, we still strive to become even better at generating new results to benefit patients,” says Jørgen H.
Olsen, Head of Research.
Cancer Research
TREATMENT OF METASTASISED CANCER
One of the most dangerous characteristics of cancer is the possibility of cells metastasising from the
original tumour. In 2012, the Danish Cancer Society presented new knowledge about a protein which is
crucial for the metastasisation of cancer cells. At the same time the researchers developed an antibody
against the protein, and animal studies show that it is extremely effective at inhibiting metastasis.
The protein behind these remarkable results is called
S100A4. Previous research has shown that the protein is an
important factor in the development and spread of cancer.
However, in 2012 researchers from the Danish Cancer
Society, among others, showed that S100A4 is upregulated in connection with brain damage. This helps to protect the nerve cells and allows for faster healing of the
tissue. And the fact that S100A4 plays a role in wound
healing is interesting because there are many similarities
between cancer and wounds that will not heal.
“The results are very interesting. Now we know that the
way in which S100A4 stimulates growth and metastasis
is by keeping the wound-like processes going,” explains
Noona Ambartsumian, senior researcher and one of the
persons behind the discovery.
be the first treatment with the ability to block metastasis,” Noona Ambartsumian says.
The researchers have patented the antibody and are now
in the process of finding partners and soliciting financial
support to develop a therapy based on the antibody. So
far, the results are a very encouraging example of how
basic research can be successfully converted into preclinical cancer treatment. And, if successful, it can save
many lives.
“Previous research has shown that S100A4 is upregulated in many types of cancer, such as breast, lung, colon,
pancreatic, prostate, etc. Thus, efficient treatment will be
a huge breakthrough in the fight against cancer,” Noona
Ambartsumian says.
Behind the research in S100A4
The group behind the new results comprises
Professor Eugene Lukanidin, senior researcher Mariam Grigorian, senior researcher
Noona Ambartsumian, and Jörg Klingelhöfer,
PhD, in close collaboration with researchers from the University of Copenhagen.
In 2012, the researchers moved from the
Danish Cancer Society to the University of
Copenhagen where they set up a team specialising in neurooncology with support from
the Danish Cancer Society. For many years,
the research team has been studying the
specific role of S100A4 in cancer, and they
have shown, among other things, that it is
the cancer cells themselves which stimulate
surrounding cells to excrete S100A4. This
probably takes place at a very early stage of
the disease and enables cancer cells to move
and metastasise in other parts of the body.
At the same time, S100A4 stimulates the
increased formation of blood vessels supplying oxygen and nourishment to the growing
cancer cells.
The photos show experiments with growing cell cultures in the lab.
Towards the first treatment
While showing that S100A4 is a key factor in preventing metastasis, the research team also developed an
antibody to block S100A4. The researchers have tested
the antibody in mice experiments and the successful
outcome was published in the scientific journal Neoplasia
at the end of the year.
“The antibody efficiently inhibits the metastasis of cancer
in mice. These results are extremely encouraging and
make us hopeful that we will be able to develop a treatment which can be used on humans. If we succeed, it will
The cells grow in a special gel in which
they can spread and mimic the processes that are involved in metastasis in
the body. The radiating arms from cell
mass are offshoots that show the cells
spreading in the gel around them.
S100A4 has been added to these cells.
This makes the cells more invasive. They
form more offshoots which grow into
the surrounding gel.
Here, antibodies against S100A4 have
been added, which inhibits the spreading
of the cells.
11
Danish Cancer Society | Annual Report 2012
KEY TO UNDERSTANDING BRAIN CANCER
Researchers from the Danish Cancer Society have made a discovery which
may increase our knowledge and understanding of how malignant brain tumours
develop. The discovery is considered essential knowledge in endeavours to improve
the treatment of glioblastoma – an aggressive type of brain tumour.
Together with senior researcher Petra Hamerlik, professor Jiri Bartek discovered the link between stem cells
from the glioblastoma tumour and the VEGFR2 protein,
whose function is to help the cancer cells create new
blood vessels. These blood vessels are essential in supplying the tumour with nourishment which allows it to
survive and spread. The researchers discovered that
the stem cells have an ‘autonomous’ signalling mechanism which enables the cells to produce both VEGF and
VEGFR2, a receptor protein attached to the cell wall
which can respond to signals from VEGF.
The mechanism functions like a key for a lock. When
the key (the VEGF protein) is inserted into the lock (the
VEGFR receptor) of the stem cells, the cells receive
a signal which helps them to protect themselves and
develop resistance to anti-VEGF medicine. This signalling mechanism also protects stem cells more efficiently
against radiation therapy.
“This new understanding of the interaction between stem
cells and the VEGFR2 protein supports long-term hopes
of designing a more efficient treatment which could block
signals from the VEGF protein and make cancer cells more
susceptible to treatment,” says Petra Hamerlik.
12
Brain cancer
Glioblastoma tumours are the most common type of
brain cancer in adults. Glioblastoma is also one of the
most aggressive types of cancer, characterised by
rapidly growing tumours and spreading of cancer cells.
The treatment, which is a combination of radiation
therapy and chemotherapy, has not yielded good
results so far. In aggregate, 1,200 new cases of brain
tumours are detected annually, and the number has
been increasing every year. Today, more than 10,000
Danes are living with the disease.
Basis for more efficient treatment
For some years, researchers have been aware that there
had to be some form of communication between the
stem cells and the VEGF protein. Based on this assumption, the researchers have tried out a new treatment
strategy of injecting a special antibody which should
block the VEGF protein, and thus keep the tumour from
growing. The treatment was a success. Unfortunately,
however, the antibodies were only effective for a short
period of time until the glioblastoma itself developed
new resistance to the antibodies after which it could
continue to grow and spread.
With the discovery of the actual communication mechanism between the glioblastoma stem cells and the VEGFR2 protein, researchers at the Danish Cancer Society, in
collaboration with Rigshospitalet and researchers in the
US, have provided doctors with a basis for developing a
more efficient treatment in the coming years, and hopefully also for improving survival rates.
The new knowledge about the signalling mechanism
and the glioblastoma was published in the prestigious
American Journal of Experimental Medicine.
Scan and learn more
If you scan the QR code below, you can see an
interview with senior researcher Petra Hamerlik.
What to do
• Download and install a free app (e.g. Scanlife)
on your smartphone and scan the code.
• Or send a text message with the word ‘scan’
to 1220. Follow the instructions and scan the code.
Please note that when using
2D codes and sending text
messages your carrier’s
standard messaging and data
charges apply and are paid via
your phone bill.
Cancer Research
VEGF secretion
VEGFR2 expression in GSC
n
io
Irradiat
VEG
F se
stra
t
ion
i
R2
GF
VE
n
tio
Angiogenesis
GSC survival
VEGF
VEGF
VEGFR2 homodimer
VEGFR2/NRP-1 heterodimer
GSC: glioma stem-like cell
EC: endothelial cell
CT: chemotherapy
Tumour relapse?
IR/CT
ibi
nh
Immunofluorescence staining of
VEGFR2 and NRP in a glioblastoma
(primary glioblastoma multiforme).
Green is VEGFR, purple is NRP1 and
blue are nuclei.
que
VEGF
sequ
estra
R2 in
hibit
tion
ion
Tumour reduction
IR/CT
Angiogenesis
GSC survival
Illustration of VEGFR2/NRP-1 signalling and
its function in Glioma Stem-like Cells (GSCs).
(A) Ionising radiation enhances the amount of
VEGFR2 and stimulates pro-survival signalling
in the cell.
(B) For a period, the substance Bevacizumab
inhibits vascularisation.
(C) Repeated series of VEGFR2-inhibiting
treatment block signalling in the cell. The
tumour shrinks when followed up by radiation
and chemotherapy.
13
Danish Cancer Society | Annual Report 2012
DISPARITY AND
CANCER
In 2012, the research unit ‘Life after
cancer’ revealed new knowledge about
social disparity and cancer survival. Studies
of three major types of cancer have shown
that social position in particular affects
how advanced the disease is when it is
diagnosed.
Researchers at the Danish Cancer Society have previously shown that socioeconomic conditions have an impact
on several aspects related to cancer, irrespective of type.
Such conditions influence the type of cancer that develops as well as the prospects of surviving it. Research also
shows that the prospects of surviving cancer improve
proportonally with the level of education and the level of
income, and that the survival rate is higher for cohabitants than for individuals who live alone.
In 2012, the researchers published the results of a more
detailed study of three types of cancer: lung cancer,
lymphoma and cervical cancer. By investigating a number
of circumstances relating to each of the diseases, the aim
was to describe the reasons behind the social disparity in
cancer survival.
One of the areas studied was the stage of the disease
at the time of detection. Furthermore, the researchers
studied whether treatment had been correct and
optimal. And finally, they examined the importance
of comorbidity, i.e. whether the patients had other
disorders or diseases when they were diagnosed with
cancer.
14
Social disparity related to stage at detection
Eye-opener for healthcare professionals
Generally speaking, lung cancer, lymphoma and cervical
cancer were at different stages at the time of detection.
The disease was detected at a more advanced stage in
patients with a short-cycle education and a low income
level and living alone.
The current results show that it would be extremely
beneficial to strive to ensure, for instance, that cancer
is detected as early as possible in all patients, and that
people who live alone and need to keep track of all their
agreements and doctor consultations on their own also
receive the best possible treatment. This effort could be
carried out through protocols, cancer plans, etc.
The results furthermore showed that non-small cell lung
cancer patients who had low income and status as singles
were more likely to undergo surgery than those who
earned more and were living in a relationship. The same
applied to patients with non-Hodgkin’s lymphoma, where
there was social and economic disparity in terms of who
received radiotherapy.
However, with respect to the importance of having one
or more disorders or diseases at the time of the cancer diagnosis, this turned out to depend on the type of
disease being studied.
“Comorbidity does not affect patients with lung cancer.
But it does have an impact on women with cervical cancer and can cause the diagnosis to be made later,” says
senior researcher Susanne Dalton.
Susanne Dalton believes that the current results ought
to be an eye-opener for healthcare professionals in their
interaction with patients.
“The results reveal a clear pattern for patients with a certain profile. A number of reasons could explain why these
particular factors make patients more vulnerable, and we
are not familiar with all of them yet. But the knowledge
we possess should sound an alarm for doctors, nurses,
and other healthcare professionals in their dealings with
patients with little education, a low income or who live
alone. They require special attention to make sure they
receive the same provision of care and an equally high
level of treatment as patients with more resourceful
profiles,” Susanne Dalton says.
Cancer Research
PROBLEMATIC TEST OF PROSTATE CANCER
The number of men who get prostate
cancer, has tripled in only 15 years. Today,
the disease is detected much earlier thanks
to increased use of so-called PSA tests. At
the same time, however, a survey from the
Danish Cancer Society has shown that this
does not affect the mortality rate, even
though the disease is generally detected
and treated earlier.
In collaboration with urologists from Rigshospitalet in
Copenhagen, the Danish Cancer Society has followed all
prostate cancer patients – almost 63,000 men – listed
in the national Cancer Registry from 1978 to 2009.
“It is true that – despite increased focus on prostate
cancer, more frequent PSA testing, earlier treatment and
more treatment options – we have yet to observe any
effect on the disease’s mortality rate,” says Søren Friis,
senior researcher and doctor.
Prostate cancer is the most frequent type of cancer in
Danish males and the second-highest cause of death.
Approx. 1,200 men die of prostate cancer every year.
A long life without symptoms
The survey suggests that the increased use of PSA testing over the past 15 years is not always an advantage for
the individual male – or for the health economy. Many
elderly men can live a long life with undiagnosed prostate
cancer which develops only slowly and does not lead
to any symptoms. The problem is that it is difficult to
distinguish between those who should be offered treatment quickly, and those who may benefit from not being
treated, and are monitored over time instead - something which would also benefit the healthcare system.
Over-treatment without effect
“The increased use of PSA testing means that prostate
cancer is often discovered at an early stage of the disease. Once diagnosed, many patients expect treatment,
even if it often has serious side-effects and may not
even be necessary since most cases of prostate cancer
develop slowly,” explains Søren Friis.
Most frequent type of cancer for men
Søren Friis fears that patients are being overtreated. In
addition, the PSA test is not very reliable. There are many
false positives, and also a certain amount of false-negative results.
“It is unlikely that this is explained by an actual increase
in the prevalence of the disease. The common use of PSA
(prostate-specific antigen) testing seems to be the primary reason that three times as many cases of prostate
cancer are diagnosed today,” Søren Friis says.
False positives of course trigger a fear in men who are actually healthy. Often this patient will still have to go through
a lengthy process of additional examinations and controls
before the prostate cancer diagnosis can be ruled out.
When should PSA testing be
performed?
A previous study showed that eight out of ten
80-year-old males with prostate cancer died
from diseases other than prostate cancer, such
as cardiovascular disease or diabetes. Consequently, it is recommended that the PSA test
only be used if a medical assessment justifies
this, or if two or more close relatives have suffered from the disease.
Treatment of prostate cancer
Not all types of prostate cancer require
treatment. For up to 50% of men diagnosed
with prostate cancer, the disease is not immediately life-threatening.
Men diagnosed with non-aggressive prostate
cancer at an advanced age should not undergo
treatment. Instead the doctor should follow the
patient over time.
The treatment of prostate cancer often has
serious side effects, such as impotence and
incontinence.
The treatment primarily consists of surgery,
radiation therapy or anti-hormone therapy. In
recent years, a number of new treatments have
been developed, such as new forms of chemotherapy and so-called prostate cancer vaccines
(immunotherapy) which seem to prolong the
survival rate.
15
Danish Cancer Society | Annual Report 2012
“But the PSA test should never be used without
thorough consideration, and general screening should
be avoided. The primary purpose of a screening test
is to reduce the mortality rate and improve the quality
of life – not to provoke illness, create unnecessary fear
or overtreatment.
False-negative results are also problematic because they
can create a false sense of security in patient and doctor
alike, as the doctor thinks the patient is healthy. Consequently, the patient will not be monitored closely enough
by the doctor.
How should PSA testing be used?
The results were published in the journal Acta Oncologica
in 2012.
“The PSA test is a good tool for doctors to make the
diagnosis, provided, however, that there are symptoms
or examinations indicating a possible prostate cancer diagnosis. As a screening tool, the indication for using PSA
testing is currently reserved for men with a hereditary
predisposition. The PSA test is also a very valuable tool
for doctors’ monitoring of patients, both those who have
been treated for the disease and those who are just being monitored over time,” Søren Friis says, adding:
Prevalence and mortality of prostate cancer
80
Prevalence and mortality of prostate cancer
80
60
20
40
0
19781982
20
1983- 19881987 1992
1993- 19981997 2002
Prevalence
Mortality
0
19781982
1983- 19881987 1992
1993- 19981997 2002
Prevalence
Mortality
Age-adjusted number of prostate cancer cases
16 per 100,000 person-years
2003- 20082007 2009
Diet, genes and environment
•Documented correlation between low levels of
vitamin D and an unhealthy lifestyle.
•The most comprehensive survey so far charting the
Danes’ vitamin D status has been launched.
•New collaboration has been set up to investigate
whether lignans, a plant substance, is an effective
weapon in the fight against cancer.
FOCAL POINTS IN 2013
The primary goal of the Danish Cancer Society Research
Center is to ensure that its research continues to be
ranked among the international elite. This means that
the Center should continue to deliver research results
which can create value for Danish cancer patients and for
cancer treatment on a global scale.
40
60
RESULTS IN 2012
Age-adjusted number of prostate cancer cases
per 100,000 person-years
2003- 20082007 2009
The merger of the former research departments to form
the new Danish Cancer Society Research Center has
been carried out as planned, but work is still in progress
to make the final pieces fall into place before the new
organisation is complete. 2013 will mark the year where
we take the last steps by forming two new research
groups.
So far, the Center consists of five research units:
Cancer Research
Statistics, bioinformatics and registers
Life after cancer
Cell death and metabolism
•Use of PSA testing to screen for prostate cancer is problematic as the test is unable to differentiate between
whether the disease will develop slowly and without
symptoms or when treatment should be offered quickly.
•Social disparity in survival rates after cervical cancer
as well non-Hodgkin's lymphoma.
•Breakthrough for research into aggressive breast
cancer. The researchers have identified part of the
network which causes breast cancer to metastasise
•New knowledge about breast cancer which is resistant
to anti-hormone therapy. Researchers have now found
an explanation of how cancer cells avoid the ‘death
signals’ activated during anti-hormone therapy.
Virus, lifestyle and genes
•Substantial decline in the occurrence of genital warts
after the introduction of the HPV vaccine.
Diet, genes and environment
•Identify environmental factors (particularly traffic pollution), work environment and lifestyles which increase
the risk of cancer and weaken the prognosis for cancer
patients
•Assess the impact of diet on the risk of cancer
•Identify genetic risk factors related to cancer
•Develop non-invasive methods for early detection of
cancer
Virus, lifestyle and genes
•New screening methods including HPV against
cervical cancer
•Monitor the effect of HPV vaccine in the Danish
population
•Assess the risk of cancer in children born to women
who had received fertility treatment
Genome integrity
• New key to understanding fatal brain cancer
•Biomarkers in connection with replication stress
and their relevance to cancer
•Early detection of cancer in female genitalia and the
breast
•Genetic-environmental interaction: impact on the
development of ovarian and breast cancer
•Identify factors which may affect the course of the
disease in women with ovarian cancer
Cell death and metabolism
•Describe the cell’s signalling systems relevant to cancer
development
•Assess the role of cell membranes in cancer development
•Chart the mechanisms associated with cellular stress
and cancer development
•Describe the molecular mechanisms which are central
to the development of treatment resistance in breast
cancer
•Find biomarkers for the development of resistance to
anti-estrogens
Genome integrity
•Identify unknown, but vital mechanisms in the cancer
cell which can be used in targeted treatment of cancer
•Chart which mechanisms keep the genome (the cell’s
hereditary material) intact despite genotoxic stress
•Epigenetic processes in cancer: Structure and function
of elements in the cell core
•Studies of the role of proteins in cancer development
Life after cancer
•Quality-of-life surveys among cancer patients
•Health consequences of cancer treatment in children
and young people
•Post-treatment health-impairment sequelae in adult
cancer survivors
•Research into how to support patients and relatives
•Create a coherent interdepartmental and intersector
cancer rehabilitation pathway in the healthcare
system
17
Danish Cancer Society | Annual Report 2012
EXTERNAL RESEARCH
Research into advanced imaging diagnostics
Ultrasound is one of the primary tools for offering individually designed therapy to patients
with upper gastrointestinal cancer. Michael Bau Mortensen, consultant doctor, PhD, has
been employed at the University of Southern Denmark in a professorship created by
the Danish Cancer Society. He will be conducting research into the potential of advanced
imaging diagnostics for helping patients who incur a life-threatening disease.
Figure 1.
Relapse of cancer
in the small pelvis.
The tumour (T)
is found by ultrasonic identification through a 12
mm port in the
patient’s stomach
(laparoscopy).
Photo: Michael
Bau Mortensen
Every year, more than 2,300 Danes are afflicted by
cancer in the oesophagus, stomach, pancreas, liver or the
biliary passage – referred to collectively as upper gastrointestinal cancer. These are life-threatening diseases, and
a prompt and precise diagnosis is crucial.
T
This is exactly the purpose of the professorship at the
University of Southern Denmark, where Michael Bau
Mortensen will be conducting research into methods that
will enable doctors to make a precise diagnosis at the
earliest possible stage of the disease.
T
T
Figure 2.
A few cm from the tumour in figure 1,
ultrasound was used to identify two
additional cancerous tumours (marked T).
Photo: Michael Bau Mortensen
18
“The combination of ultrasound examinations using
cameras and keyhole surgery gives an image of the
disease which is precise enough for us to select the best
treatment for the patient with 90% certainty. No other
investigation provides the same degree of certainty,”
Michael Bau Mortensen says.
An accurate diagnosis is crucial for providing the best possible treatment, partly by distinguishing patients who should
be offered curative surgery from patients who can only be
offered palliative treatment, and partly by tailoring therapies to individual patients and identifying patients who,
for instance, should only be offered surgery after receiving
chemotherapy or radiation therapy to reduce the tumour.
Interdisciplinary centre
Apart from imaging diagnostics research, the professor will be responsible for setting up the first centre in
Denmark to combine clinical research with basic research
in areas such as the molecular biology and genetics of
upper gastrointestinal cancer.
“We believe in the theory that many cases of upper
gastrointestinal cancer which are treated in the same way
today in fact represent diseases which are dissimilar from
a molecular point of view. Our goal is to identify cancercell markers which may reveal the optimal treatment for
the individual patient,” says Michael Bau Mortensen.
Michael Bau Mortensen is convinced that the significant
research efforts set in motion by the new professorship
will benefit the patients.
“Fast and precise diagnosis combined with a more
detailed categorisation of the patients’ diseases will
undoubtedly enable us to offer better and more individualised treatment. And at the end of the day, this will
improve the survival rate,” says Michael Bau Mortensen.
Cancer Research
Tailored post-treatment follow-up for women
Every year, some 1,600 women are diagnosed with
gynaecological cancer. Women who undergo surgery to
treat their cancer disease subsequently enter a threeto-five-year post-treatment follow-up process. Today,
the focus of the post-treatment follow-up is primarily on
physical examinations to monitor for recurrence.
“These women are usually very nervous when they show
up for follow-up visits. And even though the physical examination is reassures them, many struggle with problems
such as which symptoms to take seriously, fatigue, sexual
problems and fertility problems,” according to Mette Linnet Olesen, nurse and PhD student, Rigshospitalet.
A new research project aims to find novel ways of intensifying the tailoring of post-treatment follow-up to the
needs of the individual woman.
A research project involving
women with gynaecological
cancer aims to ensure that the
post-treatment follow-up is
tailored to the needs of the
individual woman to a much
greater extent.
The research project is based on an adapted, researchbased patient-focussed method involving the use of
reflection sheets and communication. The women are
offered two to four conversations, and prior to each
conversation, each woman will be sent a number of
reflection sheets for completion at home. The sheets
will then form the basis of the conversation she will have.
“In this way, we get to focus exactly on the challenges
and problems she is facing. One of the sheets is diseasespecific and aims to assist the woman in distinguishing
between symptoms which are ‘only’ long-term sequelae
from her treatment and symptoms which could indicate
the recurrence of cancer and to which the woman should
react immediately,” says Mette Linnet Olesen, adding:
“It remains to be seen whether this will also make women
react faster to serious symptoms than is presently the case.”
250 women in randomised study
250 women will be enrolled in the study, which will be
randomised. Half will be offered the conversations immediately after their enrolment in the project, and the other
half will receive the offer after nine months.
Mette Linnet Olesen hopes the conversations will be
instrumental in finding women who have special psychosocial challenges which they cannot overcome without
help and support.
Supplement to medical follow-up
The new nurse-based effort should be seen as a supplement to the medical follow-up carried out by doctors.
Professor Bent Ottesen, Centre Director at Rigshospitalet, has great expectations of the project.
“Our traditional post-treatment follow-up is currently
being questioned. We have been largely focussing on
detecting recurrence as soon as possible and have been
less concerned with the needs of the individual woman. I
expect that in the future, we will see the follow-up visits
as an interdisciplinary collaboration where the woman
participates on an equal footing. Individually designed
procedures will provide an optimal follow-up process,
both from a professional point of view and in the eyes of
the patients,” says Bent Ottesen.
The Danish Cancer Society supports the project with
DKK 450,000. The project is expected to be completed
in two years.
19
prevention
The Danish Cancer Society strives to ensure that knowledge
about prevention is translated into tangible improvements. With
the knowledge available today, one third of all new cancer cases
and up to half of all cancer deaths can be avoided.
All cancers except other skin cancers
Incidence: Number aged 0-18+
20000
18000
16000
14000
12000
10000
2000
2002
2004
2006
2008
2010
Men
Woman
20
Two friends, Amalie
Miang and Eva Høj Andersen,
in their GP’s waiting room
– ready to get vaccinated
against HPV.
21
Danish Cancer Society | Annual Report 2012
PREVENTION AND DOCUMENTATION
Some 36,000 Danes were diagnosed with cancer in
2012. But this doesn’t have to be the case. Roughly one
third of all cancer cases and half of all cancer deaths are
preventable if we all followed the recommendations, and
if we designed our society in accordance with the knowledge currently available.
Fortunately, things are moving in the right direction. In
2012, 120,000 Danes quit smoking, and the number
of daily smokers declined from 18% in 2011 to 17% in
2012. Another encouraging development was that the
HPV vaccine was made free of charge for many young
women in 2012, and that sun protection was included
as one of the National Health and Medicines Authority's new prevention packages aimed at assisting the
municipalities in prioritising and planning their preventive efforts. The HPV vaccination, smoking and sun
protection are also some of the areas of focus of the 64
employees and 30 student assistants in Prevention and
Documentation. Other areas include screening, physical
activity and diet. A final core area is documentation.
Prevalence, mortality and cancer survival rates consti-
tute important information when prioritising the efforts
and measuring their effects. The work at Prevention
and Documentation consists primarily in the collection
and dissemination of knowledge, conducting research
into behaviour and behavioural changes, as well as
practical and political action. Most of the activities are
carried out and funded in collaboration with external
groups, companies and authorities. The broad approach
to these tasks efforts gives the Danish Cancer Society a
unique opportunity to play a key role in the prevention
of cancer in Denmark.
NEW SMOKE-FREE WINDS
Today, 39% of all Danes are ex-smokers.
This corresponds to no less than 1.8
million people. This figure must be significantly reduced. For this dream to come
true, we first of all need to stop young
new generations from taking up smoking.
The number of Danish smokers has dropped significantly. In December 2012, a survey showed that 22%
of the adult Danish population are smokers. In 2000, this
number was 33%. Also the attitude towards smoking
has changed significantly. Today, the Act on Smoking has
become popular, and smoking indoors in a private home
is now considered more or less unacceptable. Thus in
2012, 69% said that they do not accept smoking in their
homes. In 2011, this number was only 61%.
22
The encouraging statistics derive from two nationwide surveys carried out annually by the Danish Cancer
Society in collaboration with the National Health and
Medicines Authority, the Danish Heart Foundation and
the Danish Lung Association.
Reaching the young generations
Unfortunately, the same positive developments cannot
be observed in younger generations, where the number
of smokers in 2010 was roughly the same as in 2006.
The latest figures show that 11% of the boys and 10% of
the girls in the 9th grade smoke. This explains why young
people’s smoking habits have been a focus area at the
Danish Cancer Society for years. Our activities include
Xhale, an electronic quit-smoking program which sends
text messages and emails to youths, encouraging them
to stick to their decision to quit smoking. Another effort
is the X:IT project, which provides materials and guidelines to schools and municipalities, helping them to keep
7th – 9th graders smoke-free. Fortunately, in 2012
political focus was also directed at preventing smoking
among youths. For instance, money has been allocated
through the public special pool funds for the social areas,
with Xhale and X:IT as important elements.
“X:IT is a scientifically based project, drawing partly on
lessons learned in Norway, where the number of young
smokers has successfully been reduced to 6% through rules,
education, collaboration with parents and contracts with
pupils. For almost three years, we have been running an experiment based on a similar model at 100 schools. This will
now be scaled up,” says project manager Per Kim Nielsen.
Another focus area has been the residential continuation
schools which have been criticised for years for being
an incubator for new smokers. In collaboration with the
Danish association of residential continuation schools,
Prevention and Documentation has worked to ensure
that the majority of the schools now have appropriate
smoking policies, and that they offer training and as-
prevention
Clean air for the lungs
In November, the Danish Cancer Society invited
volunteers to a workshop about future efforts
aimed at giving Danish children a smoke-free upbringing. This resulted in a project called ‘Clean Air
for the Lungs’, which will run in 2013. The aim is
to ensure that children in a childminder scheme are
not exposed to tobacco-contaminated air. As part
of the effort, volunteers work locally to influence
the municipalities to gradually introduce completely smoke-free childminder homes 24 hours a day.
sistance in how to quit smoking. At schools which collaborated with the Danish Cancer Society, the number
of smokers has been cut in half. This means that the
number of smokers at schools where smoking is prohibited amounted to 11.5%, and at schools where it is
allowed, amounted to 20.1% in 2010–2011.
New Act on Smoking
There was also focus on youths when the Act on
Smoking was amended in 2012. As the most important change, the amended act included a total ban on
smoking at childcare institutions, primary and secondary schools and continuation schools where most of
the pupils are under 18.
MORE HPV VACCINES
27 August 2012 was a good and long-awaited day at Prevention and Documentation.
From this day onwards, women born between 1985 and 1992 could see their doctor and
be vaccinated against HPV free of charge. At the same time, the day marked the launch of a
large-scale campaign aimed at encouraging young women to take advantage of this offer.
About 70% of all cases of cervical cancer are caused
by the types of HPV which the HPV vaccine protects
against. Therefore, we hope that this type of cancer can
be eliminated entirely in Denmark by means of vaccination and screening.
At the Danish Cancer Society, we strive to achieve the
highest vaccination rate in the world. The first figures indicate that we are making quick progress. The number of
vaccinated women aged 20–27 almost doubled during
the very first month in which the vaccine was provided
free of charge. This corresponds to 50,000 women who
are now far better protected against cervical cancer.
This number has grown since then. One of the reasons
for this is the campaign ‘Wonder Life Friends’ (“Veninder
for Vidunderlivet”) by means of which the Danish Cancer
Society attempts to reach the target group via Facebook,
cinema commercial spots and popular websites, and
encourage the young women to get the three injections
together with a friend.
Target group reached
Unfortunately, the act did not lead to the clampdown
at workplaces which the Danish Cancer Society had
hoped for. It is no longer allowed to smoke in individual
offices, but it is still allowed to set up designated
smoking rooms and smoking cubicles at workplaces.
An analysis of the campaign shows that the strategy has
worked so far. For instance, 87% of the target group
remembered at least one element of the campaign, and
many more had become aware of the HPV vaccine’s
existence. Before the launch of the campaign, only 56%
of the target group knew that the vaccine was free. This
number had increased to 97% after the campaign.
“Already after two months, 80,000 women had already
been vaccinated, which is extremely promising. The campaign has also rubbed off on other age groups who want
the vaccine even though they have to pay for it themselves. This is very positive, because we want as many
women as possible get the vaccine,” says Iben Holten,
consultant doctor and project manager.
Continued focus on free vaccine
In 2013, the Danish Cancer Society will continue its effort to make the HPV vaccine a free and permanent offer
for all young women up to and including the age of 26.
For women aged 20–27, the offer only runs until the
end of 2013, and there is currently no offer for women
aged 18-20 who were previously comprised by a catchup programme.
Great effort from volunteers
Volunteers at the Danish Cancer Society have distributed campaign material to more than 700 general
practitioners, and some 30 local units have ordered
the campaign material for distribution to the target
group.
23
Danish Cancer Society | Annual Report 2012
THE NUMBERS REVEAL THE DEVELOPMENTS
Intestinal cancer is sharply increasing: still more patients will need rehabilitation. Region Zealand is now ranked an undesirable first
with respect to the number of cases of lung cancer. These are just a few examples of the information available in the NORDCAN
cancer statistics database – information which the Danish Cancer Society uses for planning initiatives and taking action.
Intestinal cancer is the third most common type of
cancer, and every year almost 4,300 Danes are diagnosed with colon or colorectal cancer. This number will
increase in the years ahead according to NORDCAN data,
a publicly-available database based on Nordic cancer registries for which the Danish Cancer Society functions as
secretariat. It is estimated that the incidence of colon
and colorectal cancer in Denmark will increase by 67%
for men and 56% for women between now and 2030.
This estimate can be made because it has been possible,
since 2012, to make projections in NORDCAN until the
year 2030.
Colon and colorectal cancer
Incidence: ASR (W), men aged 0-85+
60
50
40
30
20
10
0
1982
1987
1992
1997
DK, North Denmark Region
DK, Central Denmark Region
DK, Region of Southern Denmark
DK, Capital Region of Denmark
DK, Region Zealand
24
2002
2007
“This offers a unique opportunity to predict how many
people will be afflicted with cancer in the years to come.
This is relevant, for instance, when planning a screening
programme for intestinal cancer which has long been
a wish at the Danish Cancer Society, and which will be
implemented in 2014. It also hints that we need to do
more to tell Danes about how to prevent the disease,”
according to senior statistician Gerda Engholm.
Cancer at regional level
In 2012, it became possible to retrieve data at regional
level as well. This now enables us to see how many
people develop cancer in each region, and we can
monitor whether the prevalence, mortality rate and
number of Danes living after cancer are declining or
increasing. For instance, we can see that the Capital
Region no longer has the highest number of lung cancer
cases. For both men and women, Region Zealand is
ranked first in terms of the incidence of lung cancer. The
same applies to intestinal cancer, which, like lung cancer,
is highly related to lifestyle.
“We can see that in some parts of Denmark, people have
done a better job of learning from the message that they
should quit smoking, exercise and eat a healthy diet than
in other parts of the country. There is considerable social
disparity with respect to health, which is also reflected in
cancer statistics, both in terms of the number of people
who get cancer and how they cope with their disease,”
Gerda Engholm says.
Consequently, social disparity is also a focus area when
Prevention and Documentation plans new campaigns.
An example of this is our effort to persuade all young
women – regardless of social and geographical background – to take advantage of the free HPV vaccination.
Other examples include our efforts to encourage young
people with reading difficulties to refrain from taking up
smoking.
prevention
RESULTS IN 2012
• The number of municipalities providing the flexible new
quit-smoking programme ‘Come and Quit’ (“Kom &
Kvit”) increased from 18 to 30 municipalities in 2012.
• Private and public sector workplaces have received
support to introduce smoke-free working hours and
encourage a better break culture at work.
• Methods have been developed to deal with smoking
indoors in areas where it is difficult to regulate, such as
nursing homes and hospices.
• As a consultant and project manager at a health project
at Copenhagen’s The Fortifications, the Danish Cancer
Society has made a qualitative contribution to the development of innovative activities and physical facilities
that promote playing, sports and exercise.
• SMIL – Sund Mad i IdrætsLivet (healthy food at sports
facilities) – an investigation of best practice to ensure
that a healthier diet is offered at cafeterias associated
with sports facilities.
• The Whole Grain Partnership has contributed to
ensuring that whole grain products have become
more common.
• Update of NORDCAN with 2010 data for all Nordic
countries.
• The European Cancer Registration project EUROCOURSE has been completed, and the Danish
Cancer Society’s role as responsible party for the
project on the right to privacy and high standards
of ethics in registry research has had a great impact
on new EU legislation concerning personal data.
•T
he media campaign “Switch off the Solarium” has won
three awards: Creative Circle, Aurora and the Effectiveness Award.
•V
olunteers have communicated the sun campaign’s
message to childcare institutions, youths and families
with children throughout Denmark, thus attracting attention to sun-related issues at a local political level.
•C
ontinued decline in sunbed use.
• The ‘From Car to Bike’ project.
• ‘Schoolyard Fun’ is a new partnership aimed at promoting physical activities in the schoolyard.
• The ‘Playing on a Line’ (“Leg på streg”) project.
• In the research project ‘Calorie Accounts’, the Danish
Cancer Society will collaborate with a national daily
commodity chain and the University of Copenhagen
on a survey dealing with how to make it easier for
consumers to make healthier choices without affecting
store earnings.
• Continued focus on the HPV vaccination and on women
in the target group who are difficult to reach.
• More female immigrants and refugees should participate in mass screenings for breast cancer and cervical cancer and be vaccinated against HPV. So far, 50
municipal health communicators have been trained to
inform about the free offers.
•P
resentation of the Danish data on trends in the break down of cancer stages on the individual types of cancer.
•D
evelop resources for collecting data about cancer
stages, treatment and comorbidity in relation to individual types of cancer.
•D
evelop collaboration with clinical databases.
•S
trive to achieve a ban on solariums for youths below
the age of 18.
•S
trengthen the primary sun advice, shade, in the
campaign’s communication, collaboration agreements,
structural efforts and other activities.
FOCAL POINTS IN 2013
• The evaluation of X:IT will continue at the some 100
schools that participated in the project, and the result
of the evaluation will be available in the autumn of
2013. The quit-smoking programmes Xhale and
ddsp.dk will also be evaluated.
• Xhale will become available as an app.
• Give smokers easy access to a variety of efficient
methods for quitting smoking in the municipalities.
• Further develop the ‘Healthy Together’ model to include communities other than workplaces, particularly
public housing projects.
• Smoke-free childminder facilities through volunteers in
the ‘Clean Air for the Lungs’ project.
• Smoke-free working hours.
• A new prevention and questioning panel.
25
Danish Cancer Society | Annual Report 2012
“Spending time with others
in the same situation is great,
because we simply understand each other,” says Stine
Legarth, 28, Copenhagen. She
is involved in the “Drivkræften”
network for young people with
cancer, where she functions as
a team leader in Copenhagen.
26
patient support
People suffering from cancer should be able to lead a fulfilling daily
life. The Danish Cancer Society endeavours to provide an optimal
framework of counselling and support to cancer patients.
Contacts with cancer patients, relatives
and the bereaved 2002 – 2012
Contacts
100000
80000
60000
40000
20000
0
2002
2004
2006
2008
2010
2012
27
Danish Cancer Society | Annual Report 2012
PATIENT SUPPORT
Patient Support and Community Activities strive to
make sure that all cancer patients and their relatives are
offered care, knowledge and possible courses of action
throughout their cancer pathway. At the same time, the
department aims to heighten the visibility of the needs
of cancer patients and their relatives and document
these needs. Furthermore, it aims to develop new offers
for patient support and collaborate with relevant players
to disseminate these offers.
The Danish Cancer Society currently offers counselling
to patients and relatives, either individually or in groups,
at more than 30 sites across Denmark. At most of these
sites, people may walk in off the street without having
made an appointment in advance.
The Danish Cancer Society wants to establish a framework which promotes the patient’s own scope of action,
and a space where patients and relatives can meet with
others in the same situation. In 2013, the first three out
of a total of seven new cancer counselling centres will
be inaugurated. They will all be in close proximity to the
major oncology hospitals. The project is called ‘Living
Spaces’ (“Livsrum”).
In 2012, Patient Support & Community Activities had
almost 75,000 contacts with cancer patients, relatives
and the bereaved, who received psychosocial counselling,
teaching or participated in activities at the cancer counselling centres. The Danish Cancer Society will be able
to offer help and support to far more people affected
by cancer when the new centres are ready for use in the
years ahead.
In terms of community activities, area managers, area
consultants and cancer counselling centres have actively
participated in launching the rehabilitation and palliation pathway programmes. Furthermore, there has been
focus on the preventive effort and providing assistance
to regional committees and local units.
The department has 138 employees, 102 of which work
locally throughout Denmark and 36 are based at the
Copenhagen headquarters.
LIVING SPACES – HOUSES WITH A HEALING EFFECT
The Danish Cancer Society and Realdania will build seven new cancer counselling centres
which will be located close to the major cancer treatment hospitals. The project is called
Living Spaces and the keywords are safety, homeliness and presence. The first counselling
centre will open in Næstved in June 2013.
The Danish Cancer Society is in contact with people affected by cancer – patients, relatives and the bereaved
– every day. They have one thing in common: they need
help to find their way in a new reality.
“But we know that a large group of people find it difficult
to be proactive and seek help. And many people are not
even aware of our patient support activities. We want
to change this, and this is the background for the ‘living
spaces’ project,” says Laila Walther, head of department.
28
A living space for everyone
Together with Realdania, the Danish Cancer Society will
build seven new cancer counselling centres. The new ‘living spaces’ will be built in close proximity to the oncology
departments in Aalborg, Herning, Vejle, Odense, Roskilde,
Næstved and Herlev.
In Næstved, Aalborg and Vejle, construction work is
already far advanced, and the counselling centre in
Næstved will open in June. The centres in Aalborg and
Patient support
YOUTHS WITH CANCER: YOU ARE NOT ALONE
Although there is never a good time to be diagnosed with cancer, the consequences are
especially severe for young people. They are on the threshold of life – about to begin or
complete their education, find a job, partner or start a family. The Danish Cancer Society
focuses on young people and cancer.
Vejle will follow in July and September, respectively.
Ground has been broken for the counselling centre
in Odense, and the construction of the centres in
Roskilde and Herning will start in the spring and is
expected to be finished by late 2013 or early 2014,
concurrently with the centre in Odense. In Vejle, the
counselling centre will open in conjunction with the
palliative day team, and in Odense and Aalborg, the
hospitals have decided to offer ‘Body and Cancer’
– physical exercise activities – to cancer patients receiving treatment, at the cancer counselling centres.
The last ’living space’ will be built close to Herlev
Hospital. As soon as a suitable building site becomes
available, the Danish Cancer Society and Realdania
are ready to start the project.
Useful houses
Laila Walther is convinced that users will feel welcome in the new counselling centres, because the
users of the present centres, volunteers, hospital
staff, municipalities and employees at the Danish
Cancer Society have all contributed input and ideas.
“I’m sure that this will help us build useful well-conceived houses where people will feel welcome and
comfortable,” Laila Walther states.
Realdania supports the project with DKK 50 million.
“I think and act differently from other people my own
age. I have had cancer, I have faced death, and inside my
head, I am 70 years old,” says 28-year-old Stine Legarth
from Copenhagen.
Today, Stine Legarth is a volunteer at “Drivkræften”,
the network for young people with cancer, where she
functions as a team leader in Copenhagen.
Stine Legarth was diagnosed with Hodgkin’s lymphatic
cancer in 2005. She received chemotherapy and
radiation therapy, and in 2006 she was given a clean
bill of health.
“I had no idea what to do when I found out I had cancer.
I didn’t know anybody my own age. And the patients I
met during my treatment were much older than me. I felt
very lonely,” she says.
to pass on my experiences to others. And this has been
very well received,” she says.
Isolation and loneliness
Every year, approx. 1,300 young people aged 15 to 39
are diagnosed with cancer. Incurring a life-threatening
disease in the prime of one’s youth is one thing. Having
to undergo cancer treatment at a department where the
average age usually corresponds to one’s grandparents is
another.
“Like Stine Legarth, many young people feel isolated and
lonely when afflicted with cancer. And they long to meet
other young people in the same situation. These are the
reasons we give higher priority to working with young
people through initiatives such as the ‘Drivkræften’ network,” says Laila Walther.
“Drivkræften” is growing
Inspired by a stay at the Dallund Rehabilitation Centre
with other young people with cancer, she took the initiative to start the “Drivkræften” network in Aarhus back in
2008.
“I just didn’t want other young people to feel lonely the
way I did. It was so important for me to get the chance
Since 2007, cancer patients and survivors in the age
group from 15 to 40 have had the opportunity to establish contact with other young people in the same situation
via “Drivkræften”. Today, “Drivkræften” has local network
groups in Copenhagen, Odense, Aarhus, Vejle and Aalborg,
with dedicated young people in charge of activities such
as dining together and going to the cinema together.
29
Danish Cancer Society | Annual Report 2012
“I’m a student
and sing in several
bands, so I’ve got
my hands full. But
that doesn’t mean
I’ll compromise on
my voluntary work
for Drivkræften. I
get energy from
my work there, and
I’m thrilled to be
involved in developing the offers at
Drivkræften,” says
Stine Legarth.
INCURABLE PATIENTS DO NOT GET
SUFFICIENT SUPPORT
Insufficient collaboration in the healthcare sector, dissatisfaction with efforts targeting
relatives and the failure to relieve symptoms such as pain, loss of appetite and depression.
For the first time ever, the Danish Cancer Society has identified central themes for incurable
Danish cancer patients with a short life expectancy.
The Danish Cancer Society is now working to give
“Drivkræften” much more visibility at Danish hospital
departments, the Society’s cancer counselling centres, the “Drivkræften” website, and on Facebook
– all under the motto “You are not alone”.
Launching a nation-wide survey
The Danish Cancer Society is planning a large nationwide survey to collect knowledge of the special
problems experienced by young cancer patients
during their cancer pathway.
“Our support for young cancer patients must be top
quality, so the offers are aimed at their special needs.
It is crucial that they receive much more targeted
offers to improve their quality of life,” states Laila
Walther.
30
Almost 550 severely ill cancer patients provided input
for a “Barometer Survey” by the Danish Cancer Society
concerning cancer patients’ perception of the palliative
phase of life.
Insufficient relief of symptoms
ing of not receiving sufficient care,” says Laila Walther,
head of department.
Healthcare sector collaboration must be
strengthened
One-third of the patients experienced some or serious
pain. More than half were very tired, half had no appetite
and many suffered from anxiety and depression. In the
survey, they were asked whether they felt they had received sufficient palliative care to relieve their symptoms.
Almost one-third of the patients expressed that they had
not received sufficient care.
Furthermore, the patients felt that the collaboration
between the different segments of the healthcare sector
was not up to par. One out of four patients did not have
the impression that the hospital and the GP collaborated
well. One in five did not find that there was good collaboration between the hospital, the GP and the home-care
service, and one in ten did not experience good collaboration between the GP and the palliative team/hospice.
“This is not good enough, because palliation of physical symptoms such as pain, fatigue, loss of appetite and
nausea, as well as of the severe mental stress associated
with the disease, are obvious core areas in the palliative
effort. I know that not all symptoms can be fully relieved,
but it is unsatisfactory that so many people have a feel-
“It is of crucial importance that the home-care service,
GPs, palliative teams, hospices and hospitals form a long
and coherent chain. Not until all levels of the chain use
each other in the best possible way and agree on how
to solve the task will we be able to provide a terminal
patient with optimal care,” says Laila Walther.
Patient support
RESULTS IN 2012
Neglected relatives
Across hospitals, GPs, home-care services and the
palliative teams/hospices, there was major dissatisfaction with the staff’s interest in the relatives’
situation. The same applied to the staff’s involvement
of relatives in the patients’ treatment. Every third
patient was dissatisfied with this in relation to the
hospital’s effort, and one in four expressed dissatisfaction with the home-care service in this respect.
“It is quite obvious that the healthcare sector is not
doing a good enough job in relation to the relatives.
We know how much it means to the patient that the
relatives get involved, because they constitute the
most important resource for the patient in every
respect. This is an important focus area which we
are striving to improve. The relatives need to get
involved and receive support,” says Laila Walther.
The Barometer Survey launched by the Danish Cancer Society Central Board is the most comprehensive
of its kind so far.
“Even though ‘only’ 550 patients participate in the
survey, the results are extremely important, because
they represent the experiences of a group of patients
who are rarely listened to,” says Laila Walther, and
adds:
“A major development and expansion is going on
these years when it comes to palliative care for
incurable and terminal patients. But we still have a
long way to go. One of the outcomes of this survey
will be to stimulate a discussion of how we can best
improve our efforts.”
•T
he ground has been broken for three ’living spaces’. A
winner has been found for the construction project in
Odense, and the architecture competition for Herning
and Roskilde has been announced.
•A
patient-support strategy has been developed to set
clear goals for patient-support efforts and the involvement of new target groups.
• In collaboration with the Palliative Research Unit at
Bispebjerg Hospital, a barometer survey has been
conducted which focuses on cancer patients’ needs
and experiences in the late palliative phase.
•A
t Rigshospitalet and Herlev Hospital, well-functioning
patient representative groups have been set up to advise on patients’ needs. The department has evaluated
the project and will disseminate the lessons learned.
• In connection with the implementation of the rehabilitation and palliation programme, the department has
been represented in working groups set up in the five
regions, and has organised theme days and contributed
to municipal rehabilitation efforts.
• Special focus on young people with cancer
• The Dallund Rehabilitation Centre was included in
the Finance and Appropriations Act for 2012. As at
1 January 2013, the Region of Southern Denmark took
over responsibility for this. Initially, the Centre will continue to offer rehabilitation courses to cancer patients
who have completed treatment.
FOCAL POINTS IN 2013
• Inauguration of the first three ’living spaces’.
Six construction projects in the pipeline.
• In collaboration with other departments at the Danish
Cancer Society, Patient Support will launch a Navigation Project where volunteers will be trained to help
vulnerable cancer patients navigate the treatment
pathway.
•C
ontribution to the development of digital support
offers and other digital tools which can help cancer
patients deal with their own problems and longterm sequelae. The department will establish a
network for researchers in the field and contribute
to testing four concrete digital tools.
• Offer of online counselling.
• Focus on young people with cancer and on children
whose relatives have cancer, and development of
offers targeted particularly at these groups.
• Close monitoring of the municipal rehabilitation effort
and creating a complete overview of the effort all
across Denmark.
• Follow-up on cancer patients’ needs in the palliative
phase and dialogue with professional environments
on finding solutions.
31
Danish Cancer Society | Annual Report 2012
ACHIEVEMENTS IN 2012
“Beat Ca
ncer” ra
Cancer.d
k
Cancer p
atients a
nd relativ
most imp
es are th
ortant ta
e largest
rget grou
Society’s
and
p of the
website,
Danish C
c
a
ncer.dk.
Cancer.d
a
ncer
k is one o
f the mo
Danish s
s
t compre
ites and
hensive
attracted
visitors in
almost th
2012. Th
re
e million
e
site is co
updated
ntinuous
with sup
ly
p
o
being
rt
about ca
and the la
ncer dise
test know
a
s
e
ledge
s
been enh
, and mo
st recentl
anced in
the psyc
y it has
hosocial
area.
12 FACEBOOK PAGES
Facebook is one of the media channels that the Danish
Cancer Society has made most use of to interact with users.
So far, the Society has 12 Facebook pages aimed at different target groups. ‘Support for the Breasts’ has almost
500,000 fans, which makes it one of the
largest in Denmark, whereas the Danish Cancer Society’s general Facebook profile has 180,000 fans.
ised DK
Denmark
K 100 m
’s largest
illion
e
ffort aga
million fo
inst canc
r the Dan
e
r
ra
is
ised DKK
h Cancer
43. In a n
100
Society o
umber o
n T V2 in
f shows
cancer a
a
week
ll
week lon
nd fundra
g, TV2 fo
ising. This
“Beat Ca
cused on
culminate
ncer ” fun
d
d
in the big
ra
iser show
In all, the
live
on Saturd
different
ay, 27 O
shows du
week rea
c
tober.
ring the
ched mo
Beat Can
re than 3
B eat C a n
cer
.4 million
cer live s
viewers,
how was
million D
and the
watched
anes. In o
b
y more th
n
ly
given mo
two wee
an 1.6
ks, the c
re than 1
ampaign
00,000
In week
w
li
k
as
e
s on Face
44, 89%
b o ok .
of all Dan
asked wh
es answe
ether the
red ‘yes’
y h a d se
Danish C
wh e n
en, heard
ancer So
or read a
ciety in th
week, 68
b
o
ut the
e
m
% of Dan
edia, and
es indica
in the sa
or very p
te
me
d
ositive im
that they
pression
had a po
of Beat C
sitive
ancer.
Relay for Life
More members
At the end of 2012,
466,215 private individuals
and families were members of
the Danish Cancer Society,
compared to 464,736 in 2011. The
reason for the slight membership
increase is that, as expected, there
has been a slightly larger dropout in 2012 as a result of the
membership fee increase adopted
at the meeting of the Danish
Cancer Society’s Committee
of Representatives in May.
In 2012, the Relay for Life was held in 16 cities.
Some 12,400 Danes took part in the relay races,
including 2,000 current and former cancer patients,
who are given hope by being part of the event. The
relay races raised DKK 3.2 million.
RECORD INCOME FROM LOTTERIES
Once again in 2012, the 10 lotteries yielded an
impressive income of DKK 67.5
million, against DKK 57.7 million in 2011.
Patient safety
along the cancer pathway
Under the auspices of the National Taskforce,
Quality & Patient Safety has been involved in
drawing up a set of national recommendations
which will improve the safety of cancer treatment, focussing on chemotherapy, radiation
therapy, infections, patient involvement, etc.
The taskforce has been set up in collaboration with the Danish Multidisciplinary Cancer
Groups (DMCG) and Danish Regions.
www.frivillig.dk
In October, Volunteering launched www.
frivillig.dk – the Danish Cancer Society’s
universe for volunteers. During the first
two months, almost
people
900
40,000 volunteers
Without volunteers, the Danish Cancer
Society would never be able to carry out
the Society’s ongoing tasks. In 2012, more
than 40,000 people chose to spend their leisure
time helping the Danish Cancer Society. This
equals some 560 full-time positions. “There’s no
way we could provide the amount of research
and the help we offer to cancer patients
without the huge efforts of our volunteers,” says Leif Vestergaard Pedersen,
managing director of the Danish
Cancer Society.
had created a profile. The profiles have
been used actively to post volunteer jobs,
advertise local events, establish collaborative groups, etc.
Pink Cup
Pink Cup – Denmark’s largest golf tournament for women
– raised more than DKK 3.1 million for the breast
cancer cause. Since it was begun in 2003, the Pink Cup
tournament has raised DKK 20.8 million.
g policy
teerin
New volun
g policy
volunteerin
’s
ty
e
ci
o
S
een
Cancer
ration betw
The Danish
ose collabo
cl
in
e
p
u
th
n
t
ou
was draw
ees. It sets
ng
and employ
by answeri
rk
o
w
volunteers
ry
ta
n
lu
o
v
for the
framework
ch as:
su
s
question
olunteer?
aims
ecome a v
r Society’s
Who can b
nish Cance
a
D
e
th
re
What a
rk?
luntary wo
for the vo
THE PATIENT APP
“LIVING WITH CANCER”
The Danish Cancer society won the UN ‘World Summit Award Mobile 2012’ for the
patient app ‘Living with Cancer’ (“Liv Med Kræft”). The app was developed to address the
needs of cancer patients and relatives to manage and keep track of the cancer pathway.
The app includes a number of functions which aim to make living with cancer a little bit
easier. For instance, it is possible to create a log of the cancer pathway which keeps track
of everything that has happened along the way. And it contains a checklist with possible
questions for doctors, employees, family and friends.
The users are satisfied: 80.2% are returning visitors
and 19.8% of the visitors are new. The most popular
pages are: Profile, log, checklist and calendar.
Recycling is
hot
In Septembe
r, the Danish
Cancer Soci
eleventh IGEN
ety’s
shop opened
in Odense. T
new thrift sh
he
op has got of
f to a good st
with a turnov
art
er of DKK 50
0,000 during
the first thre
e months.
More than 6
00 people do
voluntary w
in the shops,
ork
which had a
co
mbined turn
ver of approx
o. DKK 19 mill
ion in 2012.
National fundraising
More than
30,000
2.6
Danes visited
million homes
for the year's national
fundraising drive on 25
March, which raised DKK
30.5
r surveys
Baromete
and 2
1
r Surveys,
e Baromete
th
n
o
d
e
Bas
ption of
ients’ perce
cancer pat
t and follow
n
, treatme
n
io
at
in
m
aexa
been an
ospitals has
up at the h
erformed
p
rvey was
su
e
h
T
.
al,
d
lyse
ejle Hospit
tion with V
ra
o
b
lla
o
g
co
in
ve its al
ing to achie
v
ri
st
is
h
ic
wh
s when it
world-clas
g
in
m
al,
co
e
b
of
ients optim
ffering pat
o
to
s
e
m
co
therapy.
-designed
individually
million.
33
Danish Cancer Society | Annual Report 2012
Focal Points in 2013
Policy and Legal Advice
• The policy work in the Executive
Committee and Central Board of the
Society
• Pursue political goals on a national level
• Work on the Danish Cancer Society’s
goals towards 2020
Management
Policy and Legal Advice
HR
Volunteering
• Strategy for the voluntary work at
the Danish Cancer Society
• Relay for Life in seven additional
cities
• One or two more thrift shops and a
web shop for second-hand products
Volunteering
Fundraising
&
Membership
Patient Support
&
Community Activities
Fundraising & Membership
• Recruit 25,000-30,000 new
members
•T
en-year anniversary for the
Support for Breasts campaign.
Revitalisation of the campaign
• ‘Danes on Bikes’ – cycling race
attracting 15,000 participants
across 8 Danish cities. Fundraising
target of DKK 1.5m net
Patient Support & Community
Activities
• Inauguration of the first three ‘living
spaces’.
• Navigator project training volunteers
to help vulnerable cancer patients
navigate the treatment pathway
• Offer of online counselling.
Focal Points in 2013
Communications
• Strengthen the Danish Cancer
Society’s high profile in the
media and the general public
• Increase the use of social
media, including mobile units
• Increase the web TV
production at cancer.dk
Communications Department
Finances & Administration
The Danish Cancer Society
Research Center
Cancer Prevention
&
Documentation
Quality
&
Patient Safety
• Identify environmental factors
(particularly traffic pollution), work
environment and lifestyles which
increase the risk of cancer and
weaken the prognosis for cancer
patients
• Post-treatment health-impairment
sequelae in adult cancer survivors
• Chart the mechanisms associated
with cellular stress and cancer
development
The Danish
Cancer Society
Research Center
Cancer Prevention &
Documentation
• Information campaign on
intestinal cancer.
•S
trive to achieve a ban
on solariums for youths
below the age of 18.
•G
ive smokers easy
access to a variety of
efficient methods for
quitting smoking in the
municipalities.
Quality & Patient Safety
• Develop a requirements-based model to assist
the healthcare system in following up on the
patient after completed cancer treatment
• Continue to strengthen the involvement of
patients and relatives as partners in research
and development of the healthcare system
•C
arry out development projects with patients
and clinicians in order to incorporate the
patients’ own information about healthrelated vitality in clinical practice
35
Finances
From 2008 to 2012, the Danish Cancer Society’s
expenses targeting the Society’s main objectives,
etc., increased by DKK 125m to DKK 569m.
Expenses for the Danish Cancer Society’s
main objectives
DKK million
600
500
400
300
2008
36
2009
2010
2011
2012
Socialising and exercising with
like-minded people means a lot
to Mette Bloch Kristiansen, 50.
Mette was diagnosed with rectal
cancer eight years ago and has
had five recurrences since then.
“I’m currently free from
disease and treatment and back
on my job. That’s great, but it
doesn’t mean I’ll cut down on
exercising and spending time
with the others. That’s one thing
I can’t do without,” says Mette
Bloch Kristiansen.
37
Danish Cancer Society | Annual Report 2012
38
Finances
Key figures for five years
Income has grown by DKK 129.2m to a total of DKK
664.4m in the five-year period from 2008 to 2012,
equivalent to an increase of more than 24%. The most
significant increase is seen from 2011 to 2012 where
the Danish Cancer Society carried out the Beat Cancer
campaign in collaboration with TV2, focusing on the
fight against cancer through a series of events and TV
programmes.
The item Funds collected, which includes income
from legacies and bequests, membership fees, national
collections, grants for specific projects, etc., amounts to
DKK 505.3m in 2012, up DKK 116.0m or almost 30%
over the five-year period.
Legacy income has declined over the five-year period
from DKK 171.8m in 2008 to DKK 149.4m in 2012,
equivalent to a decline of DKK 22.4m or 13%. The reason for this decline is lower proceeds per legacy case.
Membership fees, etc., increased over the five-year
period from DKK 82.6m in 2008 to DKK 120.6m in
2012, equivalent to an increase of DKK 38.0m. In the
same period, the membership has increased from
430,484 to 466,215.
External grants for specific projects rose from DKK
66.5m in 2008 to DKK 96.8m in 2012, equivalent to
an increase of DKK 30.3m or almost 46%.
Income from national fundraising drives has increased
from DKK 32.7m to DKK 102.6m, equivalent to an increase of DKK 69.9m. The 2012 Beat Cancer campaign
is the most important reason for the increase, whereas
income from door-to-door fundraising has maintained
a relatively stable level of about DKK 30m in the fiveyear-period.
The profit from Lotteries, recycling and sale of goods
amounts to DKK 112.3m in 2012, which is an increase of
DKK 34.6m or almost 45% during the five-year period.
Capital income, comprising interest, dividends and
rental income received, has declined by DKK 25.9m
during the five-year period and amounts to DKK 11.2m
in 2012. The decline in this income is, to a large extent,
attributable to lower interest-rate levels during the
period, as well as declining rental income due to Denmark’s School of Design’s vacation of the Society’s
buildings in 2011.
At DKK 35.6m, Government grants reached its highest
level for the five-year period in 2012 due to grants for
the Dallund Rehabilitation Centre which was transferred
to the Region of Southern Denmark on 1 January 2013.
The Fundraising & Membership department’s regular
and project expenses, consisting of salaries and project
expenses for member services, analyses and development of new forms of income and games, amount to
DKK 68.3m in 2012. This is an increase of DKK 2.9m
compared to 2011. Compared to 2008, the aggregate
increase is DKK 14.5m, or almost 27%. The amount
should be viewed in relation to the increase in income in
the five-year period.
Research expenditure fluctuated during the period from
a low of DKK 214.0m in 2008, to DKK 278.6m in 2012.
This is an increase of DKK 64.6m, or 30% compared to
2008. From 2008 to 2009, research expenditure rose
from DKK 214.0m to DKK 279.1m which is the highest
level of spending on research in the five-year period,
mainly due to a marked increase in the distribution of
strategic funds. A higher level of distribution of strategic
funds is also the main reason for the increase in research
expenditure from DKK 240.5m in 2011 to DKK 278.6m
in 2012.
Expenses for Patient Support & Community activities
amount to DKK 131.0m in 2012, the highest level in
the five-year period, representing an increase of DKK
36.4m, or some 38% compared to 2008.
Information expenses, including expenditure on
Prevention & Documentation, Communications and
Volunteering, increased steadily during the period.
In 2012, these activities amounted to DKK 104.0m,
corresponding to an increase of DKK 22.7m, or 28%
compared to 2008.
Administrative expenses amounted to DKK 35.5m in
2012, which represents an increase of DKK 8.7m over
the five-year period. The reason is primarily a rise in
common staff expenses.
The most significant asset item is the Securities portfolio which has varied in the five-year period from a low of
DKK 541.7m in 2008 to a high in 2010 where the asset
item amounted to DKK 706.3m. In 2012, the amount
was DKK 678.2m. The fluctuations are primarily due to
value adjustments following changed interest-rate levels
and subsequent declines or increases in the securities
portfolio and handsome share price increases in 2009
and 2010, followed by sharply declining share prices in
2008 and 2011. Due to a portfolio restructure, 2012
also saw a major shift from securities to cash, precisely
on the balance sheet date, 31 December 2012.
39
Danish Cancer Society | Annual Report 2012
KEY FIGURES FOR FIVE YEARS
Income statement (DKK 1,000)
2008
2009
2010
2011
2012
389,282
77,729
37,087
31,114
421,607
94,173
25,443
30,482
452,752
96,763
24,211
28,865
415,760
98,953
12,584
28,893
505,294
112,293
11,182
35,641
535,212
571,705
602,591
556,190
664,410
-53,798
-61,809
-64,551
-65,431
-68,294
481,414
509,896
538,040
490,759
596,116
214,002
94,603
81,233
26,788
22,789
4,554
279,090
123,766
84,375
31,020
28,003
4,666
241,729
124,575
89,558
33,109
25,324
4,666
240,479
128,215
94,446
34,550
19,195
3,785
278,587
130,954
103,955
35,483
16,303
3,785
443,969
550,920
518,961
520,670
569,067
For use in subsequent years
37,445
-41,024
19,079
-29,911
27,049
Balance sheet (DKK 1,000)
2008
2009
2010
2011
2012
221,850
541,668
120,403
51,058
216,456
629,639
118,609
64,270
177,823
706,312
97,137
62,147
167,225
703,219
43,936
85,427
164,940
678,212
160,151
104,980
934,979
1,028,974
1,043,419
999,807
1,108,283
549,883
139,223
245,873
610,755
181,184
237,035
635,976
173,801
233,642
592,184
169,432
238,191
672,661
195,358
239,370
934,979
1,028,974
1,043,419
999,807
1,107,389
Funds collected
Lotteries, recycling, sale of goods, etc.
Capital income
Government grants
Total income
Expenses for the Fundraising & Membership Department’s regular and project activities
Total net income
Research
Patient Support & Community Activities
Information
Administrative expenses
Improvement of buildings and technical investments, etc.
Depreciation and amortisation
Total expenses
Properties
Securities and shares in Kræftens Bekæmpelses Forlag
Cash
Sundry receivables
Total assets
Equity
Grants for scientific work not yet used
Sundry payable expenses and legacy amounts on account
Total equity and liabilities
40
Finances
Income statement in pct.
2008
2009
2010
2011
2012
72.7
14.5
7.0
5.8
73.7
16.5
4.5
5.3
75.1
16.1
4.0
4.8
74.8
17.8
2.2
5.2
76.0
16.9
1.7
5.4
100.0
100.0
100.0
100.0
100.0
51.4
22.7
19.5
6.4
53.9
23.9
16.3
6.0
49.4
25.5
18.3
6.8
48.3
25.8
19.0
6.9
50.7
23.9
18.9
6.5
100.0
100.0
100.0
100.0
100.0
Distribution of income in pct.
Funds collected
Lotteries, recycling, sale of goods, etc.
Capital income
Government grants
Distribution of expenses in pct.
Research
Patient Support & Community Activities
Information
Administrative expenses
41
Danish Cancer Society | Annual Report 2012
Selected key information (DKK 1,000)
2008
2009
2010
2011
2012
562
619
631
646
652
Membership numbers
Membership fees, etc. received
Contribution per member in DKK
430,484
82,632
192
448,050
97,325
217
459,850
104,887
228
464,736
104,120
224
466,215
120,575
259
Gross income
Gross expenditure
Expenses for the Fundraising & Membership Department’s regular and project activities
Net income
609,454
74,242
53,798
481,414
652,773
81,068
61,809
509,896
683,905
81,314
64,551
538,040
643,055
86,865
65,431
490,759
764,787
100,377
68,294
596,116
Legacy income
Number of legacy cases completed
Proceeds per legacy case
171,796
258
666
173,557
284
611
175,473
299
587
150,768
286
527
149,379
272
549
External grants for specific projects
66,469
87,575
104,891
95,163
96,781
No. of collectors for door-to-door fundraising
Profit from door-to-door fundraising
Profit per collector in DKK
27,000
27,495
1,018
28,000
27,706
990
29,000
29,486
1,017
31,000
25,765
831
31,000
25,670
828
Profit from lotteries
44,840
57,289
53,707
57,681
67,540
Profit from events and sale of products
31,170
34,373
40,732
37,533
40,389
Government grants
31,114
30,482
28,865
28,893
35,641
-20.3
19.6
8.7
-0.6
9.5
59
59
61
59
61
No. of employees translated to man-years
Return as a percentage of securities portfolio incl. market value adjustments
Solvency ratio (Equity as a percentage of total assets)
42
Finances
2012 FINANCIAL REVIEW
Introduction
The Danish Cancer Society’s net income for the year
totalled DKK 596.1m. The year’s expenses for the Society’s activities totalled DKK 569.1m. This results in a
profit of DKK 27.0m.
Income
The gross income of the Danish Cancer Society amounts
to DKK 764.8m in the 2012 financial year, against DKK
643.1m the previous year. After deducting expenses for
activities such as lotteries, national fundraising drives,
thrift shops, other events and product sales, capital
income and expenses for the Fundraising & Membership
department’s regular and project activities totalling DKK
168.7m, the result is a total net income of DKK 596.1m,
equivalent to a increase of DKK 105.3m, compared to
last year. Out of the increase of DKK 105.3m, the profit
from the new Beat Cancer campaign amounts to DKK
91.3m.
Income 2003-2012
DKK million
800
600
400
200
0
Income from Legacies and testamentary bequests
(note 1) declined to DKK 149.4m in 2012, from DKK
150.8m in 2011. Fewer legacy cases were completed
than last year, with 272 cases in 2012 against 286 cases
in 2011. The average proceeds per legacy case are up
from DKK 0.527m in 2011 to DKK 0.549m in 2012.
Membership fees and contributions from members
and regular contributors (note 1) amounted to DKK
120.6m in 2012, against DKK 104.1m in 2011, equivalent to an increase in income of DKK 16.5m. This is
mainly due to an increase in membership fees.
At the end of 2012, 466,215 members were registered,
against 464,736 the previous year, i.e. a membership
increase of 1,479.
In 2012, the Danish Cancer Society Research Center,
information activities and Patient Support & Community
Activities received External grants for specific projects (note 1) totalling DKK 96.8m, which represents
an increase of DKK 1.6m compared to 2011.
Gross income
Net income
The item Corporate (note 1), comprising research gifts,
corporate memberships and co-promotion and events,
amounted to DKK 23.7m in 2012, against DKK 24.6m in
2011.
Gifts and grants (note 1) amounted to DKK 3.2m in
2012, against DKK 4.3m in 2011.
The annual door-to-door fundraising (note 1) was
held on Sunday, 25 March. The net profit was DKK 25.7
million, compared to DKK 25.8 million in 2011. As in previous years, the fundraising drive comprised all of Denmark’s 98 municipalities, and the door-to-door event
involved more than 31,000 volunteers as collectors,
organisers and assistants. The Danish Cancer Society’s
door-to-door fundraising continues to be the largest of
its kind in Denmark.
Income 2012
Income 2012
Income 2011-2012
DKK million
160
Corporate 4%
Capital income 2%
Corporate 4%
Specific project grants 15%
Capital income 2%
Other income 7%
Specific project grants 15%
Government
grants 5%
Government
grants 5%
Legacy income 23%
Other
income
Lotteries
10% 7%
80
Legacy income 23%
Contributions from
foundations 1%
Contributions
from
Lotteries 10%
National
collections 15%
National
collections 15%
Membership fees
18%
Membership fees
40
foundations 1%
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Contributions from foundations (note 1) amounts to
DKK 9.1m, which is an increase of DKK 2.2m compared
to last year. The increase is due to distribution of realised
capital gains.
18%
120
0
G
C
Lo
O
N
S
C
G
C
Me Le
mb gac orpo ifts ontr pecif ation tter apita over ther
rat and ibu
nm
ies
ic
l
inc
ers y in
a
i
l
n
e
co
o
e
hip co
gra tion proj coll
me nt g me
ec
ec
nts s f
fee me
ran
t
t
r
i
o
o
gra
s
m
n
ts
s
fou nts
nd
ati
on
s
43
2011
2012
Danish Cancer Society | Annual Report 2012
Door-to-door fundraising DKK 1,000 2012 2011
Income
31,545 31,625
Expenses
5,875 5,860
Net profit
25,670 25,765
Number of collectors
31,000 31,000
Beat Cancer campaign on TV2
Teamed up with TV2, the Danish Cancer Society carried
out the Beat Cancer campaign in week 43. In a number
of shows throughout the entire week, TV2 had focus
on cancer while raising money to the Danish Cancer
Society. This all culminated in the great Beat Cancer Live
fundraiser show on TV2 on Saturday, 27 October.
Beat Cancer
DKK 1,000 2012
Income
102,531
Expenses
11,214
Net profit
91,317
2011
-
The gross income from Beat Cancer 2012 totals DKK
102.5m, including the proceeds from the Beat Cancer
lottery delivered to every household. In addition to the
Beat Cancer lottery, income sources include lotteries
and donations via text messaging/phone, online donations, auctions and corporate donations. The net proceeds of Beat Cancer amounted to DKK 91.3m, which
are included under National collections at the amount of
DKK 76.5m (note 1) and under Lotteries (note 2) at the
amount of DKK 14.8m.
The Support for the Breasts campaign generated
net proceeds of DKK 7.7m in 2012 compared to DKK
44
Distribution of profits from the Beat Cancer campaign:
DKK m
7.5
15.0
7.5
Research into causes of cancer: Widening of Denmark's largest population survey,
Diet, Cancer and Health, to cover three generations
15.0
Research into prostate cancer with a focus on improved diagnosis methods and
individualised therapies
15.0
Research into cancer patients’ comorbidity and research into the social disparity that
characterises the general public health and well-being
12.0
Information campaign on colon cancer
5.0
Investigation of the patients’ assessment of the effect of their cancer treatment
aimed at preventing errors and complications in the cancer therapy 3.0
11.3
Total
91.3
Research into early diagnosis and cancer diagnosis improvements
1)
Research into rehabilitation for cancer patients during and after treatment
and support for a good life after cancer
Research into improved cancer prevention and the most effective prevention types
Ongoing support for sundry cancer projects (patient support)
1)
1)
1)
1)
The total amount of DKK 41.3m was distributed in 2012.
14.4m in 2011. The sharp decline of DKK 6.7m is mainly
due to the discontinuation of the Breast Gala on TV3 in
consequence of the new Beat Cancer partnership with
TV2. In 2012, the campaign also experienced a decline
in the proceeds from the sale of bracelets as well as a
decline in selected corporate partners.
The Danish Cancer Society fights breast cancer on
many fronts. Breast cancer is a high-profile focus area
because it affects 4,000 Danish women every year. The
profile is so high that the Danish Cancer Society has an
earmarked breast-cancer fundraising campaign: Support
for the Breasts.
Other activities, such as corporate and individual donations and the Pink Cup golf tournament, raised an additional DKK 7.0m. This means that a total of DKK 14.7m was
collected for breast cancer in 2012. In 2011, the amount
was DKK 19.6m.
Whatever is collected one year is spent the next. Regardless of the results of other collections for the Danish
Cancer Society, we can be sure that breast cancer gets
at least the proceeds from the earmarked fundraising.
The funding need is considerable, however, so the Cancer
Society adds a substantial amount to the funds collected.
Finances
Lotteries, recycling, sale of goods, etc. (note 2)
shows the profit from lotteries totalled DKK 67.5m
in 2012, against DKK 57.7m in 2011, representing an
increase of DKK 9.8m, which secures the highest total
profit from lotteries since 1991. The increase is largely
attributable to the publicity on TV2 in the week leading
up to the Beat Cancer show, which meant that the
door-to-door-delivered Beat Cancer lottery reached a
turnover of DKK 22.0m. Income from the individual lotteries continues to vary considerably, and it is therefore
expected that it will be difficult to maintain the high
level of income in this highly competitive market.
The Danish Cancer Society’s ten Thrift shops (note
2) under the IGEN brand generated their best-ever
performance in 2012. The profit was DKK 4.4m in 2012,
compared to DKK 3.9m in 2011. The increase is partly
due to the chain’s opening of shop no. 11 in Odense last
September, and partly due to success in the other shops.
IGEN
Income
Expenses
Net profit
DKK 1,000
Number of shops
Number of volunteers
2012
18,907
14,543
4,364
2011
17,192
13,246
3,946
11
672
10
546
The profit from Other events and product sales (note
2) increased to DKK 40.4m in 2012 compared to DKK
37.3m in 2011, up by DKK 3.1m. The increase is primarily
attributable to increased VAT refunds of DKK 1.8m. In
addition, the decline in breast cancer income is offset
by higher income from new activities such as Men &
Cancer and ‘Danes on bikes’/Alpe d’Huez with a total increase of approx. DKK 2.5m in 2012 compared to 2011.
Relay for Life was held in 16 cities in 2012, generating
an aggregate profit of DKK 3.2m, which is an increase of
DKK 1.4m compared to 2011. The relay events attract
more and more teams and the fundraising is more intensive than previously.
Relay for Life
DKK 1,000 2012
2011
Income
3,666
2,017
Expenses
459
210
Net profit
3,207
1,807
Expenses 2011-2012
DKK million
300
250
200
150
100
50
0
Number of participants
Number of relays
12,400
16
7,200
10
2011
2012
Re
s
ea
rc
h
Inf
Co Pa
orm
mm tie
un nt S
ati
ity up
on
Ac por
tiv t &
itie
s
Ad
mi
de Bu
pre ild
cia ing
tio im
tio
n pro
n
nis
tra
Expenses related to Fundraising & Members, department and project activities (note 3) is up DKK 2.9m
to a total of DKK 68.3m in 2012 as a result of increased
activities.
ding from the Danish Ministry of Health in the amount
of DKK 11.9m. As at 1 January 2013, the centre was
transferred to the Region of Southern Denmark.
Capital income (note 4) amounts to DKK 11.2m in
2012, against DKK 12.6m in 2011. The return on securities was at DKK 15.0m in 2012, against DKK 10.0m in
2011, which is mainly due to higher returns on shares.
Rental income resulted in a loss of DKK 3.8m in 2012.
The loss was mainly due to Denmark’s School of Design’s
vacation of premises in May 2011 and the resulting
vacancy.
Expenses
Government grants (note 5) which mainly includes
grants from the Danish pools and lottery funds and from
the Danish regions, amounted to DKK 35.7m in 2012.
Grants from the pools and lottery funds amounted to
DKK 17.5m in 2012, against DKK 18.7m in 2011. The
grants to the cancer counselling centres amounted to
DKK 6.3m in 2012, compared to DKK 7.2m in 2011. In
2012, the Dallund Rehabilitation Centre received fun-
v./
The aggregate expenses in 2012 for research, patient
support & community activities, information, administration, building improvement, technical investments,
etc., as well as depreciation and amortisation amounted
to DKK 569.1m, against DKK 520.7m in 2011, equivalent to an increase of DKK 48.4m. The increase is mainly
attributable to research expenditure which increases by
DKK 38.1m from DKK 240.5m to DKK 278.6m.
Administrative expenses (note 6) covers a number of
common functions, such as the Executive Committee,
committees and the management. This also includes finances, IT and shared property and staff administration.
These expenses amounted to DKK 35.5m in 2012, which
is DKK 0.9m higher than in 2011.
45
Danish Cancer Society | Annual Report 2012
Expenses 2012
Information 19%
Administration 6%
Research 51%
Patient Support
& Community
Activities 24%
Expenses for Improvement of buildings, technical
investments, etc., (note 7) amounted to DKK 16.3m
in 2012, against DKK 19.2m in 2011. The decline of DKK
2.9m is composed of lower expenses for improvements
of research premises and office facilities as well as higher expenses for current IT projects.
Research expenditure (note 8) amounted to DKK
278.6m in 2012, against DKK 240.5m in 2011. This
increase of DKK 38.1m is composed of higher expenses
for operating own research departments of DKK 3.8m,
an increase relating to quality & patient safety of DKK
3.1m, lower grants from the scientific committees of
DKK 19.2m and an increase of DKK 50.4m concerning
the strategic distributions.
The operation of own research departments increased
from DKK 116.2m in 2011 to DKK 120.1m in 2012. DKK
2.3m of this increase is attributable to an increase in
Externally funded projects which accounts for a total of
DKK 48.5m of the departments’ activities.
46
Grants from the research committees and the Central
Board amounted to DKK 79.0m in 2012 compared to
DKK 98.2m in 2011 and have thus declined by DKK
19.2m. The decline is primarily due to lower grants from
the Danish Cancer Society’s Scientific Committee of
DKK 19.5m from DKK 79.2m in 2011 to DKK 59.7m in
2012.
Expenses for Patient Support & Community Activities (note 9) amounted to DKK 131.0m in 2012, against
DKK 128.2m in 2011. Disregarding externally funded
projects and expenses for the Dallund Rehabilitation
Centre, the 2012 amount is DKK 105.2m, against DKK
103.5 in 2011, representing an increase of DKK 1.7m.
In 2012, expenses for the Dallund Rehabilitation Centre
aggregated DKK 11.9m. The Dallund Rehabilitation
Centre received funding from the Danish Ministry of
Health in the amount of DKK 11.9m in 2012. As at 1
January 2013, the centre was transferred to the Region
of Southern Denmark.
Information expenses (note 10) increased by DKK
9.5m to DKK 104.0m in 2012. The increase is attributable to increasing activities concerning Cancer Prevention & Documentation in the amount of DKK 4.0m,
an increase concerning Communications of DKK 2.0m,
an increase in Volunteering of DKK 1.7m, an increase in
externally funded projects of DKK 1.6m and an increase
in General information via lotteries of DKK 0.2m.
Balance sheet
The book value of the Society’s rental properties
(note 12) is DKK 164.9m in 2012, against DKK 167.2m
in 2011. Among the elements in the decline of DKK
2.3m are depreciation on rental properties of DKK 3.8m
and additions of DKK 1.5m during the year for properties conveyed by inheritance. The public land-assessment value of these rental properties is DKK 283.6m.
Sundry receivables, pre-paid expenses, etc. (note
13) increased from DKK 63.8m to DKK 83.4m in 2012.
The increase of DKK 19.6m is mainly due to amounts
receivable for the Beat Cancer campaign in October
2012, as part of the amounts are yet to be settled by
the telecom carriers.
The Securities portfolio (note 14), consisting of
bonds, shares and mortgages, is the major asset on the
balance sheet. The portfolio decreased by DKK 25.0m
to DKK 677.2m in 2012. This decline is composed of
a decline in the share portfolio of DKK 44.7m to DKK
128.2m and an increase in the bond portfolio of DKK
19.7m to DKK 545.8m.
The Danish Cancer Society follows an investment strategy of optimising returns on the Society’s assets for
the benefit of cancer patients, with due consideration
for composing a widely diversified, prudent and conservative portfolio. To implement this strategy, the Society
works with some of the most renowned asset managers,
which are Nykredit Asset Management, Danske Capital,
Nordea Investment Management and PFA Kapitalforvaltning.
The operating fund (note 15) amounted to DKK
398.0m at the end of 2012, against DKK 447.7m at the
end of 2011. The operating fund was allocated in 2013,
as the Central Board has approved activities of DKK
470.9m. The elements in the decline of DKK 49.7m are
the profit of the year of DKK 27.0m less a Reserve for
Beat Cancer and a Reserve for Strategic initiatives of
DKK 50.0m and DKK 26.7m respectively.
Finances
Distribution among main activities in 2012
for the Society’s 652 employees
Composition of assets
Assets totalling DKK 1,108m.
Securities
61%
Cash 14%
Administration 62
Fundraising &
Membership 91
External research
departments 43
Properties 15%
Own research
departments 189
Receivables 10%
Reserve for Beat Cancer distribution (note 16). It
was decided to distribute the profit of DKK 91.3m from
the Society’s Beat Cancer campaign to already described initiatives. DKK 41.3m were used in 2012, and DKK
50.0m consequently remain for subsequent distribution.
This amount has been placed in a special reserve. The
amount is taken from the operating fund.
Reserve for strategic initiatives (note 17). It was decided in 2009 to earmark DKK 30.0m a year from 2010
to 2019 for strategic research initiatives, corresponding
to a total of DKK 90.0m for the years 2010, 2011 and
2012. By the end of 2012, a total of DKK 63.3m of
these funds had been used, and the accumulated underconsumption amounts to DKK 26.7m. This amount was
taken from the operating fund in 2012 and placed in a
special reserve.
The Value adjustment fund (note 18) amounts to DKK
133.9m at the end of 2012. Compared to last year, this
Patient Support
& Community
Activities 165
Information/
Communications 102
is an increase of DKK 53.4m. This increase is composed
of a capital gain on bonds and shares of DKK 35.0m and
DKK 19.7m, respectively, and a foreign exchange loss of
DKK 1.3m.
Interest rate risk/Price risk
The latent price risk resting on the Society’s bond portfolio, with a duration of 3.0 (average remaining term),
will result in a decrease of DKK 16.2m, if the interest
rate increases by 1%. The Society’s value adjustment
fund, amounting to DKK 133.9m at year-end 2012, will
thus be able to counter a price decline in the bond portfolio corresponding to an interest rate increase of 8.3%.
Number of employees
The Society employed 652 FTEs at the end of 2012,
representing an increase of 6 FTEs compared to the
previous year. 232 employees work with research, compared to 229 last year, 165 employees work in Patient
Support & Community Activities, against 161 last year,
and 102 employees work with information and communications, against 105 last year. 91 employees are engaged in fundraising activities, against 89 last year, and 62
employees work with administration, which is the same
as the year before.
Management of foundations
The revaluation reserve (note 19) amounts to DKK
64.0m. In 2008, the Danish Cancer Society established
a revaluation fund, under which the Society’s rental properties at Strandboulevarden in Copenhagen’s Østerbro
district were written up by DKK 108.0m. In 2010, DKK
44.0m of this revaluation were reversed in consequence
of a decline in the property assessment value and
uncertainty relating to the future tenancy.
Grants for scientific work provided, but not yet
used (note 21) amounts to DKK 195.4m. The amount
comprises grants provided for multi-year research
projects which will be paid out as and when the projects
are implemented.
The Danish Cancer Society manages seven independent
foundations whose profits accrue to the Danish Cancer
Society in accordance with the charters’ stipulations. At
the end of 2012, the capital value of these foundations
was DKK 213.8m, against DKK 208.6m last year. The
foundations’ returns, amounting to DKK 5.9m in 2011,
are recognised in the accounts under “Funds collected”.
The asset management departments of Danish banks
manage a number of funds held on trust for interest
payment to legatees. The capital of these trust funds
was computed to be DKK 54.9m at the end of 2011.
When the interest payments cease, the capital will accrue to the Danish Cancer Society in whole or in part.
47
Danish Cancer Society | Annual Report 2012
Outlook for 2013
The Danish Cancer Society’s forecast for 2013 is a modest decline in income compared to 2012, when gross
income amounted to DKK 764.8m, which was up DKK
121.7m compared to 2011.
An important reason for this is the changed prerequisites for the large new fundraising campaign, Beat Cancer,
developed in cooperation with TV2 and aired on TV2
throughout week 43, culminating in a gala fundraiser
show. This new initiative was the primary reason for the
substantial growth in overall income in 2012. However,
the Beat Cancer campaign is not expected to reach the
same high level of income in 2013, as the campaign will
probably be subject to restrictions on the daily amount
which may be donated by text messaging. And this will
have a decisive impact on the result.
Some uncertainty is still expected, particularly in relation
to legacy income, which is the Society’s largest source
of income. However, based on the small increase in
proceeds per inheritance case in 2012, the total legacy
income is expected to increase slightly in 2013.
As a large part of the membership fee increase was
already implemented in 2012, only a minor increase in
membership income is expected in 2013. At the same
time, a targeted effort aimed at enhancing loyalty and
minimising membership decline will be launched, and the
intensive member recruitment efforts will be continued as the target of 500,000 members has yet to be
reached.
In 2012, the profit from the lotteries increased by DKK
10m, among other things due to the Beat Cancer campaign which placed extraordinary focus on the Danish
48
Cancer Society’s November lottery. The performance of
the individual lotteries throughout the year can fluctuate
greatly, and the chances of maintaining the same high
performance in 2013 are consequently subject to some
uncertainty.
Out of the operating fund, reserves have been allocated
for Beat Cancer funds of DKK 50.0m that have not yet
been distributed. Similarly, reserves have been allocated
for the funding of strategic initiatives in the amount of
DKK 26.7m which has not yet been disbursed.
An increase in corporate income is expected in 2013, as
an intensive effort will be made in particular to develop
the corporate involvement in the Beat Cancer campaign
into larger and long-lasting partnerships. The corporate
income related to Beat Cancer is included in the financial
statements of the Beat Cancer campaign.
One aim of the value adjustment fund is to ensure that
capital losses on the securities portfolio do not impede the Society’s planned level of activities. The fund
amounted to DKK 133.9m at the end of 2012.
In addition, corporate fundraising continues to be
developed – focussing on partnerships with respect to
major companies and donations with respect to smaller
companies. Campaigns and events are often pivotal for
such partnerships, and the related corporate income is
expected to increase somewhat in 2013.
The equity of the Danish Cancer Society
The Society’s equity, consisting of the Society’s operating fund, the Beat Cancer reserve, the reserve for
strategic initiatives, value adjustment fund and revaluation fund, amounts to DKK 672.7m at the end of 2012,
against DKK 592.2m in 2011. The equity thus increased
by DKK 80.5m in 2012, following the year’s profit of
DKK 27.0m and value adjustments of DKK 53.4m.
The profit for the year of DKK 27.0m is transferred to
the Operating fund which balances at DKK 398.0m
at the end of the 2012. The Operating fund is used
for funding the 2013 budget, which balances at DKK
470.9m (see note 15).
The revaluation fund amounted to DKK 64.0m at the
end of 2012.
It is the policy of the Danish Cancer Society that funds
earned in one year are to be used in the following year.
This results in a time lapse or lag between the receipt of
the income and the incurring of the expense, whereby
funds are temporarily amassed. Such funds which remain to be used are temporarily invested in securities to
obtain a better return for the benefit of the fight against
cancer, as mentioned in the section on securities.
SIGNATURES BY THE MANAGEMENT AND THE EXECUTIVE COMMITTEE
Statement by the management on the Annual Report
The Executive Committee and the management have discussed and approved the financial statements for the financial year 1 January – 31 December 2012 for the Danish Cancer
Society on the date written below.
The financial statements have been presented in accordance with the requirements for the presentation of financial statements stipulated by the Articles of Association and in accordance with generally accepted accounting principles.
In our opinion, the financial statements give a true and fair view of the Society’s assets and liabilities and its financial position at 31 December 2012 and of the results of the Society’s
activities for the financial year 1 January – 31 December 2012.
In our opinion, the management’s review gives a true and fair account of the matters addressed in the review.
The financial statements are hereby approved.
Copenhagen, 16 April 2013
Management
Leif Vestergaard Pedersen
Managing Director
Executive Committee
Frede Olesen
Chairman
Ester Larsen
Vice-chairman
Ejnar Pedersen
Jan Bjørn Nielsen
Michael Vad
49
Danish Cancer Society | Annual Report 2012
INDEPENDENT AUDITORS’ REPORT
To the members of the Central Board of the
Danish Cancer Society
we comply with ethical requirements and plan and conduct our audit to obtain reasonable assurance that the
financial statements are free from material misstatement.
Statement on the financial statements
We have audited the financial statements (pages 51 65) for the Danish Cancer Society for the financial year
1 January – 31 December 2012, comprising accounting
policies, income statement, balance sheet and notes. The
financial statements have been prepared in accordance
with generally accepted accounting policies.
The management’s responsibility for the financial
statements
The management is responsible for the preparation of
financial statements giving a true and fair view in accordance with the Danish Financial Statements Act. The
management is also responsible for internal controls
considered necessary by the management for preparing
financial statements that are free from material misstatement, whether due to fraud or error.
The auditors’ responsibility
It is our responsibility to express our opinion of the financial statements on the basis of our audit. We have conducted our audit in accordance with international auditing
standards and additional requirements in pursuance of
Danish auditing legislation and the Executive Order on
financial statements and audit of financial statements for
recipients of grants from the pools of the Danish Ministry
of Finance under the Act on certain games, lotteries and
wagers. Those requirements and standards require that
50
An audit includes performing procedures to obtain audit
evidence for the amounts and disclosures in the financial statements. The audit procedures selected depend
on the assessment made by the auditor, including the
assessment of the risk of material misstatement in the
financial statements, notwithstanding whether such
misstatement is due to fraud or error. In making such
risk assessment, the auditor considers internal controls
that are relevant to the company’s preparation and fair
presentation of financial statements in order to design
audit procedures that are appropriate under the circumstances, but not with the objective of expressing an
opinion on the efficiency of the internal control made by
the company. An audit also includes an assessment of
the appropriateness of the accounting policies applied
and the accounting estimates made by the management
together with an evaluation of the overall presentation of
the financial statements.
nancial position at 31 December 2012 and of the results
of the Society’s activities for the financial year 1 January
– 31 December 2012, in accordance with generally accepted accounting principles.
Statement on the management’s review
We have read the management’s review and the financial
review. We have not performed any further procedures in
addition to the audit performed of the financial statements.
On this basis, it is our opinion that the information in the
management’s review is in accordance with the financial
statements.
Copenhagen, 16 April 2013
Deloitte
Statsautoriseret Revisionsaktieselskab
In our view, the audit evidence obtained is sufficient and
appropriate to provide a basis for our audit opinion.
Our audit has not given rise to any qualification.
Opinion
In our opinion, the financial statements give a true and
fair view of the Society’s assets and liabilities and its fi-
Henrik Wellejus
state-authorised public accountant Christian Sanderhage
state-authorised
public accountant
Finances
ACCOUNTING POLICIES
The accounting policies are unchanged compared to last
year.
The financial statements are presented in accordance
with generally accepted accounting principles.
Capital income
BALANCE SHEET
Capital income comprises accrued interest income and
expenses, dividends and yields as well as rental income
less operating expenses for rental properties.
Properties
Government grants
The financial statements reflect the year’s financial
decisions/grants, regardless if they are not realised until
subsequent years.
Government grants are carried as income at the time of
receipt.
Buildings designated for rental purposes are valued at acquisition cost plus costs of improvement and revaluations
and less depreciation. Buildings are depreciated at an
annual rate of 2 percent. Buildings for own activities and
their costs of improvement are charged to the income
statement in the acquisition year.
Expenses
INCOME STATEMENT
Funds collected
Legacies and testamentary bequests are recognised as
income upon completion of the final estate inventory
and receipt of the legacy or bequest whereas payments
received on account are recognised on the balance sheet
under the item Legacy amounts on account for later
determination.
Expenses are accounted for on a normal accruals basis.
The expenses are attributed directly to the departments/
activities consuming the funds. Common expenses for
operating the premises at Strandboulevarden, IT, etc.,
are charged to the individual activities in accordance with
their consumption.
Inventory and laboratory equipment, etc., is charged to
the income statement at the time of acquisition.
Research grants/multi-year projects
Contributions from members and foundations as well as
corporate contributions, gifts and grants are recognised
as income at the time of realisation.
Grants received for specific research projects are recognised as income as and when utilised.
Grants for one-year or multi-year research projects are
charged to the income statement at the time of granting.
Grants provided, but not yet used, at the balance sheet
date, are recognised as payables under the item Grants
for scientific work not yet used.
Properties appropriated by inheritance, which are destined for resale or which are subject to residence rights,
etc., are recognised at the original appropriation values.
Revaluations are recognised in equity under Revaluation
fund.
Securities
Listed bonds and shares are measured at market value at
the end of the financial year. Mortgages, etc., are recognised at an estimated, conservative value.
Realised and unrealised capital gains and losses are recognised directly in the value adjustment fund.
Extraordinary items
Income from collections is recognised when the final collection results are available.
Income or expenses not attributable to the Society’s
ordinary activities are recognised as extraordinary items.
Lotteries, etc.
Proceeds from lotteries are recognised as income when
the individual games are completed.
Sale of materials, etc. is recognised as income at the time
of invoicing.
51
Danish Cancer Society | Annual Report 2012
Income statement
Note
2012
2011
1
2
505,294
112,293
415,760
98,953
617,587
514,713
-68,294
-65,431
549,293
449,282
11,182
35,641
12,584
28,893
596,116
490,759
-35,483
-16,303
-3,785
-34,550
-19,195
-3,785
540,545
433,229
-278,587
-130,954
-103,955
-240,479
-128,215
-94,446
Expenses for main objectives
-513,496
-463,140
Net profit (loss) for the year
27,049
-29,911
(DKK 1,000)
Income-generating activities
Funds collected
Lotteries, recycling, sale of goods, etc.
Total income from income-generating activities
Expenses for the Fundraising & Membership Department’s regular and project activities
3
Profit from income-generating activities
Other ordinary income
Capital income
Government grants
4
5
Total net income
Administrative expenses
Improvement of buildings for own activities
Depreciation and amortisation
6
7
12
Profit for distribution for the objectives of the Danish Cancer Society
Research
Patient Support & Community Activities
Information
52
8
9
10
Finances
Balance sheet
(DKK 1,000)
Note
2012
2011
11
12
992
164,940
1,010
167,225
165,932
168,235
83,395
21,585
677,220
160,151
63,842
21,585
702,209
43,936
942,351
831,572
1,108,283
999,807
398,021
50,000
26,752
133,888
64,000
447,724
80,460
64,000
672,661
592,184
207,237
6,533
894
25,600
195,358
191,751
1,362
806
44,272
169,432
435,622
407,623
1,108,283
999,807
Assets
Shares in Kræftens Bekæmpelses Forlag ApS
Properties
Total non-current assets
Sundry receivables, pre-paid expenses, etc.
Balance with sundry foundations
Securities
Cash
13
14
Total current assets
Total assets
Equity and liabilities
Operating fund
Reserves for Beat Cancer distribution
Reserves for strategic initiatives
Value adjustment fund
Revaluation fund
15
16
17
18
19
Total equity
Payable expenses, etc.
Balance with sundry foundations
Balance with Kræftens Bekæmpelses Forlag ApS
Legacy amount on account for later determination
Grants for scientific work not yet used
Total liabilities
Total equity and liabilities
20
21
53
Danish Cancer Society | Annual Report 2012
NOTES TO THE 2012 FINANCIAL STATEMENTS
(DKK 1,000)
Gross
income
Direct
expenses
Profit
2012
Profit
2011
149,379
120,575
96,781
9,072
23,668
3,244
-
149,379
120,575
96,781
9,072
23,668
3,244
150,768
104,120
95,163
6,895
24,599
4,326
402,719
-
402,719
385,871
31,545
87,743
5,875
11,215
25,670
76,528
25,765
-
423
46
377
4,124
119,711
17,136
102,575
29,889
522,430
17,136
505,294
415,760
112,225
18,907
52,760
44,685
14,543
12,371
67,540
4,364
40,389
57,681
3,946
37,326
183,892
71,599
112,293
98,953
NOTE 1
Funds collected
Legacies and testamentary bequests
Membership fees and contributions from members and private contributors
Grants for specific projects
Contributions from foundations
Corporate
Gifts and grants
National collections
National collections
Beat Cancer
Breast cancer month (Breast gala and Support for the Breasts)
Total funds collected
NOTE 2
Lotteries, recycling, sale of goods, etc.
Lotteries *)
Thrift shops
Other events and product sales
Total, lotteries, recycling, sale of goods, etc.
*) The Beat Cancer lottery is recognised with a net income of DKK 14.8m. In 2012, DKK 21.6m were paid out as winnings and related tax.
54
Finances
(DKK 1,000)
2012
2011
18,554
49,740
17,890
47,541
68,294
65,431
7,770
-11,560
11,994
-9,408
-3,790
2,586
-179
6,259
8,939
-47
427
7,120
2,442
9
14,972
9,998
11,182
12,584
17,493
6,249
11,899
18,743
7,146
3,004
35,641
28,893
NOTE 3
Expenses for the Fundraising & Membership Department’s regular and project activities
Operation of Department
Project expenses (member care, analyses and development of new games and maintenance of existing games)
Total expenses for the Fundraising & Membership Department’s regular and project activities
NOTE 4
Capital income
Rental income
Expenses related to operation of rental property
Result of rental operations
Bank interest income
Bond yields
Share dividends
Other income, etc.
Total capital income
NOTE 5
Government grants
Pools and lottery funds
Grants from the regions to the cancer counselling centres
Grants from the regions to the Dallund Rehabilitation Centre
Total government grants
55
Danish Cancer Society | Annual Report 2012
2012
2011
8,055
8,148
4,300
11,547
3,433
8,066
7,885
4,225
10,729
3,645
35,483
34,550
Improvement of buildings and technical investments, etc.
Research premises
Office premises
Portal project
Expenses related to torrential rain storm, net
4,700
4,339
7,030
234
17,545
1,378
272
Improvement of buildings and technical investments, etc.
16,303
19,195
(DKK 1,000)
NOTE 6
Administrative expenses
Central Board, committees and Management and Policy & Legal Advice
Finance and asset management
Property management
Common staff expenses & HR
Canteen
Total administrative expenses
NOTE 7
56
Finances
2012
2011
71,588
48,488
70,052
46,180
120,076
116,232
1,557
1,597
10,144
7,000
59,673
3,982
15,340
79,150
4,263
14,787
78,995
98,200
Research professorships
Palliation and pain
Late sequelae
Adjustment of grants
Research schools
10,000
7,500
7,500
-250
-
5,000
471
Total strategic funds
24,750
5,471
16,951
8,125
4,255
11,234
2,500
75
3,850
4,289
3,765
-
Total new strategic funds *)
43,065
11,979
Total research (see note 21)
278,587
240,479
(DKK 1,000)
NOTE 8
Research
The Danish Cancer Society Research Center
Externally funded projects
Total, operation of own research departments
Research grant administration
Quality & Patient Safety
Grants from the Danish Cancer Society’s Scientific Committee
Grants from the Psychosocial Cancer Research Committee
Grants from the Executive Committee and the Central Board (note 8A)
Total grants
Live Life, main account
Live Life, Centre for Intervention Research
Symptom and diagnosis, cancer disease diagnostics in Aarhus
Rehabilitation, strategic palliation
Centre for Integrated Rehabilitation of Cancer Patients
NKF – National Research Centre for Rehabilitation
*) Including distributions of DKK 30.0m covered by the profit from Beat Cancer.
57
Danish Cancer Society | Annual Report 2012
2012
2011
921
2,779
3,523
2,543
900
1,126
414
1,934
1,200
879
817
5,678
2,502
1,800
1,251
1,092
402
366
-
15,340
14,787
12,038
9,656
49,430
18,525
2,433
4,744
8,393
12,854
9,823
48,347
18,048
4,254
5,322
4,809
Externally funded projects
105,219
13,836
103,457
13,154
Dallund Rehabilitation Centre
119,055
11,899
116,611
11,604
130.954
128.215
(DKK 1,000)
NOTE 8A
Grants from the Executive Committee and the Central Board
Grants for researchers’ participation in congresses, etc.
Grants for other projects, etc.
Management framework
Nordic Cancer Union
Intestinal project Central Denmark Region
Documentation centre
Membership fee, Danish Patients
Repayments to the Hejmdal Joint Foundation
Research, water damage
Regional Chemotherapy, Herlev
Total grants from the Executive Committee and the Central Board
NOTE 9
Patient Support & Community Activities
Patient Support & Community Activities, management
Cancer line
Cancer Counselling Centres
Community volunteering
Patients’ associations
Patient grants
Projects and other activities
Total, Patient Support & Community Activities
58
Finances
2012
2011
Information
Cancer Prevention & Documentation
Communications
Volunteering
General information through lotteries
29,932
23,175
13,753
2,638
25,983
21,182
11,990
2,359
Externally funded projects
69,498
34,457
61,514
32,932
103,955
94,446
1,010
-18
985
25
992
1,010
(DKK 1,000)
NOTE 10
Total information
NOTE 11
Shares in Kræftens Bekæmpelses Forlag ApS
Balance, 1 January
Net profit for the year
Balance, 31 December
(The Society holds all shares)
59
Danish Cancer Society | Annual Report 2012
2012
2011
Rental properties
Acquisition price, 1 January
Disposals
142,276
-
142,276
-
Acquisition price, 31 December
142,276
142,276
Revaluation, 1 January
Disposals
64,000
-
64,000
-
Revaluation, 31 December
64,000
64,000
Depreciation, 1 January
Depreciation for the year
-44,847
-3,785
-41,062
-3,785
Depreciation, 31 December
-48,632
-44,847
157,644
161,429
Properties appropriated by inheritance, subject to residence rights, etc.
Balance, 1 January
Additions during the year
Disposals during the year
5,796
1,500
-
12,609
-6,813
Balance at 31 December
7,296
5,796
164,940
167,225
(DKK 1,000)
NOTE 12
Balance, 31 December
(Property valuation as at 1 October 2011: DKK 283,596,000)
(Property valuation as at 1 October 2011: DKK 8,833,000)
Total properties
Properties utilised for own activities are charged to income in the acquisition year. As at 1 October 2011, the public land-assessment value of these properties is DKK 278,404,000.
Settlements, etc.
Properties subject to lifelong residence rights and special obligations of use are carried as assets under “Properties” at the amount of DKK 7.293,000.
60
Finances
2012
2011
2,705
4,158
76,532
2,547
4,264
57,031
83,395
63,842
Securities
Bonds
Shares
Mortgages, etc.
545,815
128,205
3,200
526,100
172,909
3,200
Total securities
677,220
702,209
(DKK 1,000)
NOTE 13
Sundry receivables, pre-paid expenses, etc.
Accrued bond yield
Deposits concerning leases
Receivables and pre-paid expenses
Total sundry receivables, pre-paid expenses, etc.
NOTE 14
61
Danish Cancer Society | Annual Report 2012
2012
2011
447,724
27,049
-50,000
-26,752
477,635
-29,911
-
398,021
447,724
Breakdown of the operating fund
Approved 2013 expenditure budget:
Research
Strategic funds
Patient Support & Community Activities
Information
Administration and shared staff expenses
Used for construction and building works and building depreciation, etc.
163,461
28,758
95,943
65,027
42,326
5,750
%
41
7
24
16
11
1
2013 expenditure budget for the Fundraising & Membership Department
401,265
69,681
(DKK 1,000)
NOTE 15
Operating fund
Balance, 1 January
Net profit for the year
Reserves for Beat Cancer
Reserves for strategic initiatives
Balance, 31 December
100
470,946
Covered by income in 2013
-72,925
398,021
NOTE 16
Reserves for Beat Cancer distribution
Beat Cancer profit 2012
Distributed during the year
62
91,317
-41,317
-
50,000
-
Finances
2012
2011
Reserves for strategic initiatives
Provisions
Used in previous years
Distributed during the year
90,000
-20,183
-43,065
-
Balance, 31 December
26,752
-
80,460
35,077
19,678
-1,340
13
94,341
7,421
-21,379
-388
465
133,888
80,460
64,000
-
64,000
-
64,000
64,000
(DKK 1,000)
NOTE 17
NOTE 18
Value adjustment fund
Balance, 1 January
Value adjustment, bonds
Value adjustment, shares
Value adjustment, currency
Value adjustment, properties appropriated by inheritance
Balance, 31 December
NOTE 19
Revaluation fund
Balance, 1 January
Write-downs of rental properties
Total revaluation fund
63
Danish Cancer Society | Annual Report 2012
2012
2011
958
31,194
1,378
38,664
135,043
1,306
31,645
1,340
41,126
116,334
207,237
191,751
Grants for scientific work not yet used
Balance, 1 January
Granted during the year from the scientific committees, the Executive Committee and the Central Board (see note 8)
Distributed during the year
169,432
278,587
-252,661
173,801
240,479
-244,848
Balance as at 31 December for use in 2013 and later
195,358
169,432
157,245
20,643
17,470
122,193
31,039
16,200
195,358
169,432
(DKK 1,000)
NOTE 20
Payable expenses, etc.
A tax, etc. payable
Calculated holiday pay obligations
Deposits and pre-paid rent
Accounts payable
Received grants from providers of external funds not yet used
Total payable expenses etc.
NOTE 21
The grants have been given for use in
2013
2014
2015 and later
64
Økonomi
2012
2011
285,175
41,554
1,327
275,674
39,838
1,315
328,056
316,827
Representation of this amount in the financial statements
Wages and salaries for research, patient support & community activities, information and administration
Wages and salaries for income-generating activities
260,042
45,372
251,093
43,040
Total wages and salaries
305,414
294,133
22,642
22,694
328,056
316,827
652
646
(DKK 1,000)
(Notes not referred to in the financial statements)
Breakdown of the total amount for staff wages, etc.
Wages and salaries *)
Contributions for pension-related purposes
Share of expenses for social security
Total
*) No fee has been paid to the Presidium, Central Board and Executive Committee.
Wages and salaries included in grants used
Total wages and salaries paid out
Average number of employees
Contingent liabilities
The Danish Cancer Society has granted a deficit guarantee of up to DKK 1.5m a year. The liability is effective for a period of 10 years.
65
Danish Cancer Society | Annual Report 2012
Management, committees and organisation
The Presidium
•P
resident: Professor Linda Nielsen
•V
ice-president: Per Larsen, special advisor, former
assistant commissioner
•V
ice-president, Jes Dorph-Petersen, reporter/TV
presenter
The Executive Committee
•C
hairman: Professor Frede Olesen, MD
•V
ice-chairman: Ester Larsen, MA, former minister
of health
• J an Bjørn Nielsen, consultant doctor
• E jnar Pedersen, former chief municipal executive
•M
ichael Vad, managing director
The Central Board
•C
hairman: Professor Frede Olesen, MD, Århus
•V
ice-chairman: Ester Larsen, former minister of health,
Kerteminde
•B
irgitt Bjerre, courier, Nykøbing F
•A
lice Skjold Braae, former purchasing manager,
Fårevejle
•C
laus Foged, architect, Hjørring
•S
øren Gade, managing director, Holstebro
•H
ans Grishauge, head of secretariat, Copenhagen
•M
ai-Britt Guldin, psychologist, PhD, Egå
•H
enrik Harling, chief consultant doctor, MD, Holte
•B
irthe Harritz, adult supervisor and local councillor,
Tjele
•H
elle Ibsen, GP, Haderslev
•N
iels Them Kjær, project manager (staff
representative)
•C
harlotte Fabricius Kragh, MSc (nursing), associate
professor, nurse, Kirke Eskildstrup
•G
rethe Kristine Kristensen, nurse, Vojens
•O
rla Kastrup Kristensen, farm owner, Aars
66
•S
usanne Ursula Larsen, consultant doctor, Odense
• Jan Bjørn Nielsen, consultant doctor, Odder
• J ørgen Nielsen, attorney-at-law, Dronninglund
• E jnar Pedersen, former chief municipal executive,
Hornslet
•R
onni Sølvhøj Pedersen, PhD student, Copenhagen
•T
ove Pedersen, chair of local unit, Vodskov
•C
harlotte Scheppan, Director, Odense
•N
adja Brøndsted Sejersen, MA student (sociology),
Copenhagen
• Lisa Sengeløv, head consultant doctor, MD,
Copenhagen
• Anette Sloth, managing senior nurse, Thisted
•H
enrik Steenberg, human resources associate,
Copenhagen
•A
nne Tjønneland, head of department, consultant
doctor, PhD, MD (staff representative)
• Michael Vad, managing director, Hellerup
• Lisbeth Winther, city council member, Gentofte
• Gina Øbakke, former mayor, adult education teacher,
Rødvig Stevns
Board of Management
• Leif Vestergaard Pedersen, managing director
• Hans Henrik Storm, head of department
• Jørgen H. Olsen, research director
• Laila Walther, head of department
Executive Group
• Kurt Damsgaard, communications manager
• Charlotte Dehlie, HR manager
• Bjarne Heide Jørgensen, head of department
• Thomas Norling Kielgast, financial director
and administrative manager
• Janne Lehmann Knudsen, quality manager
• Poul Møller, fundraising manager
• Jørgen H. Olsen, research director
• Leif Vestergaard Pedersen, managing director
• Hans Henrik Storm, head of department
• Laila Walther, head of department
• Una Jensen Hallenberg, head of department
The Danish Cancer Society’s Scientific Committee
• Chairman: Professor Henrik Ditzel, MD,
consultant doctor, University of Southern Denmark
• Vice-chairman: Professor Cai Grau, MD,
consultant doctor, Aarhus University Hospital
• Professor Michael Baumann, MD, director, National
Center for Radiation Research in Oncology, Dresden
• Professor, Michael Borre, MD, PhD, Aarhus University
Hospital, Skejby
• Professor Marianne Ewertz, MD, consultant doctor,
Odense University Hospital
• Professor Sten L. Christer Höög, PhD,
Karolinska Institute, Stockholm
• Professor Klas Kärre, MD, PhD, Department of Microbiology, Tumor and Cell Biology (MTC), Stockholm
• Ulrik Lassen, MSc Medicine, PhD, consultant doctor,
Finsen Centre, Rigshospitalet
• Professor Jiri Lukas, DVM, PhD, managing director,
University of Copenhagen
• Professor Anders Henrik Lund, PhD, University of
Copenhagen
• Professor Elsebeth Lynge, MSc (soc.), University of
Copenhagen
• Professor Gillian Murphy, PhD, Department of
Oncology, Cambridge University
• Professor Kim Overvad, consultant doctor, PhD,
Aarhus University
• Professor Sven Påhlman, University Hospital MAS,
Malmö
• Henrik Sengeløv, MD, consultant doctor, Rigshospitalet
Management, committees and organisation
Psychosocial Research Committee
Local Units Committee
• Chairman: Signe Vikkelsø, associate professor, MSc
(psychology), PhD, Copenhagen Business School
• Vice-chairman: Professor Lene Koch, D Phil., University
of Copenhagen
• Niels Viggo Hansen, MA, PhD, centre manager,
University of Copenhagen
• Professor Marianne Jensen Hjermstad, PhD,
Oslo University Hospital
• Marianne Lau, MD, consultant doctor, Stolpegård
Psychotherapeutic Centre in Gentofte
• Susanne Dalsgaard Reventlow, MD, GP, MSc
(anthropology), research manager, associate honorary
professor, University of Copenhagen
• Professor Per Sjøgren, consultant doctor, MD,
Rigshospitalet
• Professor Jens Søndergaard, PhD, University of
Southern Denmark
• Professor Tine Tjørnhøj-Thomsen, PhD, MSc
(anthropology), University of Copenhagen
• Chairman: Henrik Frostholm, special consultant
• Ole Peter Andersen, local unit chairman
• Ejner Frøkjær, local unit chairman
• Connie Yilmaz Jantzen, centre manager
• Anne Kjaer, policy and strategy consultant
• Ulla Solvang, relaxation teacher
• Birgitte Uldall, local unit chairman
Patient Support Committee
• Chairman: Ida Sofie Jensen, group CEO
• Marie-Helene Olsen, managing senior nurse
• Ulla Svendsen, manager
• Mikael Kristensen, medical executive
• Tina Brændgaard, MA
• Anders Korsgaard Christensen, head psychologist
• Margit Maltesen, GP
• Dorthe Crüger, medical executive
Prevention and Information Committee
• Chairman: Professor Bente Klarlund Pedersen, MD,
consultant doctor, Rigshospitalet
• Vice-chairman: Suzanne Aaholm, hospital director,
Hillerød Hospital
• Professor Gert Almind, MD
• Troels Borring, chairman, Danish association of
residential continuation schools
• Peter Bork, managing director, Provendo ApS
• Professor Bjarne Ibsen, research and centre manager,
University of Southern Denmark
• Jes Søgaard, MA (social science)
• Lizette Risgaard, vice-president of the Danish
Confederation of Trade Unions
67
Danish Cancer Society | Annual Report 2012
Research – Grant holders
Aarhus, Rikke
Adamsen, Lis
Alsner, Jan
Andersen, Anni Hangaard
Andersen, Claus Lindbjerg
Andersen, Lars Dyrskjøt
Andersen, Mads Hald
Andreasen, Peter André
Assenholt, Jannie
Bartek, Jiri
Beierholm, Anders Ravnsborg
Blaakær, Jan
Borre, Michael
Brünner, Nils
Buus, Christian
Bøtkjær, Kenneth Alrø
Chakera, Annette Hougaard
Christensen, Camilla Laulund
Christensen, Lisbeth Lydiksen
Christensen, Marianne
Skovgaard
Christoffersen, Nanna Rønbjerg
Clausen, Rasmus Prætorius
Clemmensen, Knut Kristoffer
Bundgaard
Cour, Karen la
Danielsen, Allan Vestergaard
Daugaard, Gedske
Ditzel, Henrik Jørn
Drzewiecki, Krzysztof Tadeusz
Ebbesen, Maria Schou
Ehlers-Hansen, Charlotte
Erler, Janine
Ewald, Jesper Dupont
Falk, Sarah
Friis, Søren
Gaist, David
Gajhede, Michael
Geisler, Christian Harmann
Golas, Mariola Monika
68
160
179
173
1
51
93
50
2
52
3
53
183
92
54
129
4
94
55
131
5,6
7
8
130
180
132
174
95
56
133
134
58
135
9
121
122
10
96
11
Graungaard, Anette Hauskov
161
Groth, Anja
12
Grum-Schwensen, Birgitte
13
Grønbæk, Kirsten
57
Grønbæk, Morten
177
Grønvold, Mogens
97, 176
Gupta, Ramneek
59
Hadrup, Sine Reker
60
Hansen, Karina Kiilerich
14
Hansen, Klaus
15
Hansen, Niels Viggo
162
Hansen, Steen Henning
16
Hansen, Stine Ninel
61
Hartmann, Rune
17
Helin, Kristian
18
Hellwege, Sofie
136
Henriksen, Nina
163
Hickson, Ian David
19
Hjalgrim, Henrik
118
Hokland, Peter
62
Holmgaard, Rikke Bæk
63
Horsman, Michael Robert
20
98
Hutchings, Martin
Høeberg, Mikkel
64
Høyer, Morten
65
138
Idorn, Manja
Illemann, Martin
21
22
Issinger, Olaf-Georg
Jakobsen, Lis
23
Jakobsen, Merete Demant
164
Jensen, Anders Bonde
182
25
Jensen, Kim Bak
Jensen, Niels Frank
66
Jensen, Torben Heick
26
Jepsen, Lene Østergaard
165
Joensen, Eydbjørg Gaard
139
Johansen, Christoffer
186
Johansen, Julia Sidenius
67
24
Jäättelä, Marja Helena
Kallunki, Tuula Anneli
27
99
Kehlet, Henrik
Khadem, Talie Alsadat Hadi
137
Kielsen, Katrine
140
Kjær, Andreas
100
Klitkou, Jakob
141
Knox, Jeanette Bresson
Ladegaard
166
Krejsgaard, Thorbjørn Frej
28
29
Kriegbaum, Mette Camilla
Kristensen, Stine Bjørn
142
68
Lassen, Ulrik
Laurberg, Søren
101, 175
69
Laurberg, Tinne
30
Lukanidin, Eugene
31
Lukas, Jiri
Lund, Anders Henrik
32
Lundqvist, Johan
33
Mailand, Niels
34
Mandrup, Karen Riiber
35
Mayorca, Alejandro E.
36
Melbye, Mads
88
70
Mellemgaard, Anders
Meyts, Ewa Rajpert-De
71
Mikkelsen, Marianne
37
Mirza, Mansoor Raza
102
Mischorr-Boch, Christina Vigel 169
Mohammad, Ladan Ghulam
143
Mortensen, Michael Bau 103, 184
Mosbech, Christiane
144
Hammershaimb
Myer, Toshis
38
Müller, Klaus Gottlob
104
Møller, Johanne Rask
145
Møller, Lisbeth Birk
39
Mørch, Lina Steinrud
123
Neergaard, Mette Asbjørn
182
Nielsen, Claus Vinther
124
Nielsen, Dorte Lisbet
105
Nielsen, Mads
89
Nielsen, Nikolaj
40
Nielsen, Olaf
41
Nilbert, Mef
119
Obling, Anne Roelsgaard
167
Oest, Anders
146
Offersen, Birgitte
106
Olsen, Jørn
125
Olsen, Sidsel Bering
147
Osler, Merete
171
Ostenfeld, Marie Stampe
72
Ottesen, Bent
168
Overgaard, Jens
107
Palner, Mikael
42
Pedersen, Astrid Munk
148
Pedersen, Bjørn Panyella
43, 44
Pedersen, Lotte Bang
45
149
Pedersen, Tina Gerbek
Petersen, Lone Kjeld
108
Poulsen, Hans Skovgaard
73
Poulsen, Marie Louise Mølgaard 74
Poulsen, Per Rugård
75
Poulsen, Thomas Bjørnskov
46
76
Ralfkiaer, Elisabeth
109
Rosenschöld, Per Munck af
Rottmann, Nina
126
150
Rudkjøbing, Laura Aviaja
Rugbjerg, Katrine
127
Rødsten, Kirstine
151
Salanti, Ali
47
Sandelin, Albin
77
Schmidt, Henrik
110
Schmiegelow, Kjeld
111
Schrøder, Henrik
112
Schüz, Joachim
90
Sengeløv, Henrik
113
Sindrup, Søren Hein
78
Sisman, Yagmur
152
Sjøgren, Per
181, 185
Skyt, Peter Sandegaard
79
Sperling, Cecilie
170
114
Svane, Inge Marie
Svendsen, Lars Bo
187
Søes, Signe
153
Søgaard, Alexandra
80
Sørensen, Anders Lindholm
154
Sørensen, Boe Sandahl
115
Sørensen, Brita Singers
81
Sørensen, Claus Storgaard
48
155
Sørensen, Eva Futtrup
Sørensen, Karian Dalsgaard
82
83
Sørensen, Morten Dræby
84
Sørensen, Tine Thurison
116
Tanderup, Kari
Thorn, Sofie
156
157
Tjørring, Julie Mie
158
Tolstrup, Rikke
172, 178
Vedsted, Peter
128
Vestergaard, Mogens
85
Vindeløv, Lars Lindhardt
Vinten, Ea Rebekka
159
Wewer, Ulla Margrethe
49
Wille-Jørgensen, Peer Anders 117
Winther, Jeanette Falck
120
91
Wiuf, Carsten
Zachariae, Bobby
174
86
Ødum, Niels Feentved
87
Ørntoft, Torben Falck
Grants
Grants from The Danish Cancer Society's Scientific Committee (KBVU)
NB: The list contains projects in progress in 2013
which were granted support in 2012 or earlier, as
well as projects granted support in 2012 for use
in 2012.
* G
rants awarded prior to 2012 and charged
to the income statement in previous financial
statements.
£
rants for research projects being conducted
G
at the Danish Cancer Society’s own research
departments.
Grants for research projects being conducted at
other research departments.
Basic research
*1. Improved cancer therapy with
epidophyllotoxins, anthracyclines
and camptothecins by inactivating
specific DNA repair factors.
Anni Hangaard Andersen, lic. scient., PhD,
associate professor
Department of Molecular Biology,
Aarhus University
Granted for 2011-2013: DKK 1,350,000
2. Inhibition of the tumour-biological
functions of matriptase.
Professor Peter André Andreasen, DSc
Department of Molecular Biology and
Genetics, Aarhus University
Granted for 2013-2015: DKK 2,250,000
*£3. Maintaining genome integrity and its
influence on tumour formation and the
effect of cancer therapy.
Jiri Bartek, PhD, head of department
Genome integrity, Danish Cancer Society
Research Center
Granted for 2013-2015: DKK 4,740,000
*4. New methods for targeting cancer
metastasis: Development of
therapeutic inhibitors against
protein-degrading enzymes.
Kenneth Alrø Bøtkjær, MSc
Cambridge Cancer Research Institute,
Cambridge University, UK
Granted for 2012-2014: DKK 1,800,000
5. Development of cancer therapy
targeted against members of the DNA
polymerase ß super family.
Marianne Skovgaard Christensen, MSc, PhD
Sir William Dunn School of Pathology, UK
Granted for 2013-2014: DKK 1,298,100
6. Development of cancer therapy
targeting members of the DNA
polymerase ß super family.
Marianne Skovgaard Christensen, MSc, PhD
Period of study at Sir William Dunn School
of Pathology, UK
Granted for 2013-2015: DKK 81,514
*7. Cellular control mechanisms for
microRNA-mediated regulation of
gene expression in cancer.
Nanna Rønbjerg Christoffersen, MSc, PhD
Biotech Research and Innovation Centre
(BRIC), University of Copenhagen
Granted for 2011-2013: DKK 1,800,000
*8. Development of lysine histone
demethylase inhibitors for epigenetic
prostate cancer therapy – a new
pharmacological tool.
Rasmus Prætorius Clausen, MSc, PhD,
associate professor
Department of Medicinal Chemistry,
University of Copenhagen
Granted for 2011-2013: DKK 1,200,000
9. Cancer pain signalling – investigating
the role of the P2X7 receptor in pain
development.
Sarah Falk, MSc
Study visit at Department of Neuroscience,
Physiology and Pharmacology, England
Granted for 2012-2013: DKK 29,400
*10. Identification of molecules that are
potential medicines targeting the
suspected breast-cancer oncogene
KDM5B.
Professor Michael Gajhede, MSc, PhD
Department of Medicinal Chemistry,
University of Copenhagen
Granted for 2012-2013: DKK 1,200,000
*11. Identification of molecular mechanisms
responsible for development of highly
aggressive brain cancer in children.
Mariola Monika Golas, MSc Medicine, MSc,
PhD
Department of Anatomy, Aarhus University
Granted for 2012-2014: DKK 1,350,000
*12. The implications of replication stress
for epigenetic cellular changes and
cancer development.
Anja Groth, MSc, PhD, associate professor
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2012-2014: DKK 2,250,000
*£13. Blocking tumour-promoting immune
cells to inhibit the metastasis of
primary tumours.
Birgitte Grum-Schwensen, MSc, PhD
Department of Tumour Microenvironment
and Metastasis, Institute of Cancer Biology,
Danish Cancer Society
Granted for 2012-2013: DKK 1,200,000
14. GPCR signalling pathways in breast
cancer metastasis.
Karina Kiilerich Hansen, MSc, PhD
NIDCR, National Institutes of Health, USA
Granted for 2013-2014: DKK 1,200,000
*15. Identification and characterisation
of new recruitment proteins for
polycomb proteins and their role in
cell specification and cancer.
Klaus Hansen, MSc, PhD, associate professor
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2012-2014: DKK 1,800,000
*16. Characterisation of a new mechanism for
the tumour-suppressor function of the
cell-cell adhesion molecule E-cadherin.
Steen Henning Hansen, MD
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2012-2014: DKK 1,800,000
*17. Interferon lambda in cancer development and chronic viral infections.
Rune Hartmann, PhD, associate professor
Centre for Structural Biology, Aarhus University
Granted for 2011-2013: DKK 1,200,000
*18. Function of the TET2 protein in
haematopoiesis and cancer.
Professor Kristian Helin, PhD, director
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2012-2014: DKK 6,000,000
*19. Identification of the role of the
PICH protein, a presumed tumour
suppressor, in the maintenance of
chromosome stability.
Professor Ian David Hickson, PhD
Department of Cellular and Molecular
Medicine, University of Copenhagen
Granted for 2011-2013: DKK 4,200,000
69
Danish Cancer Society | Annual Report 2012
*20. Identification and targeted treatment
of microenvironment and vascular
factors in tumours with a view to enhancing the effect of radiation therapy.
Michael Robert Horsman, PhD, MD,
associate professor
Department of Experimental Clinical
Oncology, Aarhus Hospital
Granted for 2012-2014: DKK 1,350,000
21. Characterisation of different growth
patterns in hepatic metastases:
gene-expression profiling and the
implications of the extracellular matrix.
Martin Illemann, MSc (Engineering), PhD
Study visit at McGill University Health
Center, Canada
Granted for 2012-2013: DKK 38,160
*22. CK2, a druggable kinase – Investigation of the function and regulation of
multiple signalling pathways in human
cancers under normoxia and hypoxia.
Professor Olaf-Georg Issinger, Dr.rer.nat.habil.
Department of Biochemistry and Molecular
Biology, University of Southern Denmark
Granted for 2011-2013: DKK 1,950,000
*23. Functional analysis of new centrosomal
proteins for investigating the
importance of centrosome cycles
in cancer development.
Lis Jakobsen, MSc, PhD
Department of Biochemistry and Molecular
Biology, University of Southern Denmark
Granted for 2012-2013: DKK 1,200,000
*£24. Regulation of autophagy – a future
strategy for cancer therapy.
Professor Marja Helena Jäättelä, MD
Apoptosis Laboratory, Institute of Cancer
Biology, Danish Cancer Society
Granted for 2012-2014: DKK 4,500,000
70
25. Stem cells and intestinal cancer
– a new diagnostic tool.
Kim Bak Jensen, MSc, PhD, team leader
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2013-2015: DKK 2,400,000
26. Connections betwen non-coding RNA,
the nuclear exosome and cancer.
Professor Torben Heick Jensen, PhD
Department of Molecular Biology and
Genetics, Aarhus University
Granted for 2013-2015: DKK 2,250,000
*£31. Structure and function of molecular
mechanisms regulating the genotoxic
stress-induced anti-cancer barrier.
Jiri Lukas, DVM, PhD, Centre Director
Novo Nordisk Foundation Centre for Protein
Research, University of Copenhagen
Granted for 2011-2013: DKK 4,500,000
32. Identification and analysis of cancerrelated non-coding RNA molecules.
Professor Anders Henrik Lund, MSc, PhD
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2013-2015: DKK 2,500,000
*37. Therapeutic vaccine against chronic
hepatitis C virus infection.
Marianne Mikkelsen, MSc, PhD
Department of Infectious Diseases,
Hvidovre University Hospital
Granted for 2012-2013: DKK 400,000
*38. The importance of histone
demethylases in UV-induced DNA
damage in Caenorhabditis elegans.
Toshia Myer, PhD
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2011-2013: DKK 1,800,000
£27.Analysis of new regulators of
ErbB2-induced cell invasion.
Tuula Anneli Kallunki, DSc, PhD, team leader
Cell death and metabolism, Danish Cancer
Society Research Center
Granted for 2013-2015: DKK 1,650,000
33. Molecular mechanisms in vitamin
D-induced regulation of aromatase.
Johan Lundqvist, PhD pharm.
Study visit at Stanford University, USA
Granted for 2012-2013: DKK 41,400
28. The role of bacterial toxins in
development of colon cancer.
Thorbjørn Frej Krejsgaard, MSc, PhD
Department of International Health,
Immunology and Microbiology,
University of Copenhagen
Granted for 2013: DKK 600,000
34. Molecular regulation of translesion DNA
synthesis, a double-edged sword for
cancer development.
Professor Niels Mailand, PhD
Novo Nordisk Foundation Centre for Protein
Research, University of Copenhagen
Granted for 2013-2015: DKK 2,250,000
*29. Studies comprising function and
expression of the structural
homologues C4.4A and Haldisin in
benign and malignant skin lesions.
Mette Camilla Kriegbaum, MSc
Finsen Laboratory, Rigshospitalet
Granted for 2012-2014: DKK 1,350,000
35. Development of methods for risk
assessment of xenobiotic chemicals’
influence on the onset of breast cancer.
Karen Riiber Mandrup, MSc Veterinary
Medicine
Study visit at Fox Chase Cancer Center, USA
Granted for 2012: DKK 28,300
*£30. The organ-micro environment for
development of cancer metastases.
Professor Eugene Lukanidin, MD, DSc.
Department of Molecular Cancer Biology,
Institute of Cancer Biology, Danish Cancer
Society
Granted for 2010-2012: DKK 900,000
36. Prevention of lymphatic metastases by
recreating homeostasis in the stroma of
lymph nodes.
Alejandro E. Mayorca, MSc Dental Science.
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2013-2015: DKK 1,800,000
39. Primary cilia and signalling in Tuberous
Sclerosis Complex.
Lisbeth Birk Møller, MSc, PhD, senior
researcher
Kennedy Centre, Capital Region of Denmark
Granted for 2013-2015: DKK 1,650,000
40. Function of ion transport proteins in
pancreatic stellate cells.
Nikolaj Nielsen, MSc
Study visit at Institute of Physiology II,
Westfälische Wilhelms-Universität Münster,
Germany
Granted for 2012-2013: DKK 10,000
*41. Genome stability mediated by
Ddb1-Cul4-Cdt2 ubiquitin ligase.
Professor Olaf Nielsen, MSc, PhD
Department of Biology, University of
Copenhagen
Granted for 2012-2013: DKK 450,000
*42. In vivo fluorescent imaging of specific
cancer types.
Mikael Palner, MSc
Department of Radiology,
Stanford School of Medicine, USA
Granted for 2012-2014: DKK 1,800,000
Grants
*43. Characterisation of the Ptch1/Shh
complex: structure and functional
implications.
Bjørn Panyella Pedersen, MSc, PhD
Molecular Structure Group,
University of California, USA
Granted for 2011-2013: DKK 1,800,000
*44. Characterisation of the Ptch1/Shh
complex: structure and functional
implications.
Bjørn Panyella Pedersen, MSc, PhD
Scholarly visit to Molecular Structure
Group, University of California, USA
Granted for 2011-2014: DKK 232,100
45. Transport of PDgFR alpha to the
primary cilium.
Lotte Bang Pedersen, MSc, PhD, associate
professor
Department of Biology, University of
Copenhagen
Granted for 2013: DKK 259,000
Claus Storgaard Sørensen, MSc, PhD,
associate professor
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2012-2014: DKK 1,800,000
*49. Enzymes, including proteases and
kinases, and their key function in
cancer invasion.
Professor Ulla Margrethe Wewer, MD
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2012-2014: DKK 1,950,000
Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements:
DKK 25,825,874
* Granted before 2012 and charged to the income
statement in previous financial statements.
Basic and clinical research
*46. Mechanistic investigation of rakicidin A
– a new hypoxia-selective anti-cancer
natural substance.
Thomas Bjørnskov Poulsen, MSc, PhD
Department of Chemistry,
Aarhus University
Granted for 2012-2014: DKK 900,000
*50. Attacking immunosuppressed proteins:
a new cancer vaccine strategy.
Professor Mads Hald Andersen, civil engineer, DTechn, PhD
Centre for Cancer Immune Therapy (CCIT),
Herlev Hospital
Granted for 2011-2013: DKK 1,800,000
47. Malaria proteins in cancer therapy and
diagnostics.
Ali Salanti, MSc, PhD, associate professor
Department of International Health,
Immunology and Microbiology, University
of Copenhagen
Granted for 2013: DKK 750,000
*51. Cancer-specific genomic rearrangements, a basis for personalised
treatment of colorectal cancer.
Claus Lindbjerg Andersen, PhD, associate
professor
Clinical Institute, Skejby Hospital
Granted for 2012-2014: DKK 1,650,000
*48. New role for the breast cancer proteins
BRCA2 and PALB2 in the DNA damage
response.
52. Cancer-specific 3’UTR alterations in
colorectal cancer consequences,
mechanism and potential clinical
implications.
Jannie Assenholt, MSc, PhD
Department of Clinical Medicine,
Aarhus University
Granted for 2013-2014: DKK 1,200,000
*53. Tissue-equivalent, time-resolved
dose verification of advanced radiation
therapy.
Anders Ravnsborg Beierholm, MSc
Radiation Therapy, Herlev Hospital
Granted for 2012-2013: DKK 1,200,000
*54. An innovative approach to
individual-based treatment of
metastatic colorectal cancer.
Professor Nils Brünner, MD
Department of Veterinary Disease Biology,
University of Copenhagen
Granted for 2011-2013: DKK 1,250,000
55. Establishment of murine transgene
small-cell lung cancer models for
identification and testing of new
treatment goals.
Camilla Laulund Christensen, MSc
Medical Oncology, Dana-Farber Cancer
Institute, USA
Granted for 2013-2014: DKK 1,279,300
*56. Lipofilling with MSC-enriched fat
tissue, a permanent autologous filler?
Professor Krzysztof Tadeusz Drzewiecki,
MD
Department of Plastic Surgery, Breast Surgery and Burns Treatment, Rigshospitalet
Granted for 2012-2013: DKK 900,000
57. Causes of DNA hypermethylation in
haematological cancer.
Kirsten Grønbæk, MD, consultant
Department of Haematology,
Finsen Centre, Rigshospitalet
Granted for 2013-2015: DKK 1,800,000
58. Tumour endothelial marker 8 (TEM8)
as target for blocking tumour growth.
Janine Erler, MSc, PhD, team leader
Biotech Research & Innovation Centre
(BRIC), University of Copenhagen
Granted for 2013-2015: DKK 3,050,000
*59. The importance of genetic
polymorphisms for long-term sequelae
after testicular cancer therapy.
Ramneek Gupta, MSc, PhD
Department of Systems Biology, Technical
University of Denmark
Granted for 2012-2014: DKK 1,800,000
*60. Unravelling T-cell immunity directed at
Merkel Cell Polyomavirus.
Sine Reker Hadrup, MSc, PhD
Centre for Cancer Immune Therapy (CCIT),
Herlev Hospital
Granted for 2011-2013: DKK 1,360,000
61. Identification and early validation of
biomarkers for docetaxel – sensitivity
in breast cancer.
Stine Ninel Hansen, MSc
Study visit at Ontario Institute for Cancer
Research, Canada
Granted for 2012: DKK 22,230
*62. Can the hMICL protein be the link
between the paradigms of leukemic
stem cells and minimal residual disease
– myeloid leukemias as a model system.
Professor Peter Hokland, MD
Clinical Institute, Aarhus Hospital
Granted for 2012-2014: DKK 1,500,000
63. Blocking the immunosuppresant
proteins CTLA-4 and IDO in cancer.
Rikke Bæk Holmgaard, MSc, PhD
Memorial Sloan-Kettering Cancer Center,
USA
Granted for 2013-2014: DKK 1,200,000
71
Danish Cancer Society | Annual Report 2012
64. Identification and characterization
of new membrane-localized TIMP-1
interaction partners.
Mikkel Høeberg, MSc
Study visit at Beijing Institute and
Genomics, Chinese Academy of Sciences,
China
Granted for 2013: DKK 25,200
65. Biologically optimised stereotactical
radiation therapy of hepatic tumours.
Professor Morten Høyer, MSc Medicine,
PhD
Department of Oncology, Aarhus University
Hospital
Granted for 2013-2015: DKK 1,690,000
66. Molecular mechanisms for resistance to
oxaliplatin or irinotecan in human colon
cancer cell lines.
Niels Frank Jensen, MSc
Study visit at National Cancer Institute,
National Institutes of Health, USA
Granted for 2012: DKK 27,700
*67. Identification of microRNA in serum and
tissue as biomarkers of early diagnosis,
treatment response and prognosis in
pancreatic cancer patients.
Professor Julia Sidenius Johansen, MSc
Medicine, MD
Department of Oncology, Herlev Hospital
Granted for 2012-2013: DKK 1,400,000
*68. In vivo metabolism and growthinhibiting trials with specific
tyrosine kinase inhibitors in
glioblastoma multiforme
Ulrik Lassen, MSc Medicine, consultant
Finsen Centre, Rigshospitalet
Granted for 2012-2014: DKK 1,800,000
69. Local recurrence of breast cancer in
young women – a molecular genetic
72
study of age-related prognostic tumour
markers.
Tinne Laurberg, MSc Medicine
Study visit at BC Cancer Agency, Canada
Granted for 2012 - 2013: DKK 41,400
70. Incidence of EML4-AKT gene
rearrangement among patients with
pulmonary adenocarcinoma.
Anders Mellemgaard, PhD, consultant
Department of Pathology, Rigshospitalet
Granted for 2013: DKK 245,500
*71. Degree of differentiation and genetic
and epigenetic profiles of testicular
cancer in relation to prognosis:
Implications for individual therapy.
Ewa Rajpert-De Meyts, MD, PhD
Department of Growth and Reproduction,
Rigshospitalet
Granted for 2012-2014: DKK 1,350,000
*72. Identification and characterisation
of circulating exosomes in bladder
cancer patients with focus on mRNA
and non-coding RNA.
Marie Stampe Ostenfeld, MSc, PhD
Department of Molecular Medicine
(MOMA), Skejby Hospital
Granted for 2011-2013: DKK 1,350,000
73. Identification and evaluation of new
points of attack for treating patients
with glioblastoma multiforme.
Hans Skovgaard Poulsen, MD, consultant
Radiation Biology Laboratory, Finsen Centre,
Rigshospitalet
Granted for 2013-2015: DKK 1,500,000
*74. Genetic variability in von Hippel-Lindau
disease (vHL).
Marie Louise Mølgaard Poulsen, medical
student
Department of Cellular and Molecular
Medicine, University of Copenhagen
Granted for 2011-2013: DKK 1,350,000
75. Determination of real-time tumour
movement and its application for
dynamic tumour tracking during
radiation therapy.
Per Rugård Poulsen, PhD, physicist,
associate professor
Department of Oncology,
Aarhus University Hospital
Granted for 2013-2015: DKK 1,650,000
*76. MicroRNA expression and function in
T-cell lymphomas.
Professor Elisabeth Ralfkiaer, MD, consultant
Department of Pathology, Rigshospitalet
Granted for 2012-2014: DKK 1,050,000
*77. Finding alternative splice types and
alternative promoters for Acute
Myeloid Leukaemia.
Albin Sandelin, MSc, PhD, associate professor
Bioinformatics Centre, University of Copenhagen
Granted for 2011-2013: DKK 1,200,000
78. Oxaliplatin-induced polyneuropathy in
patients treated for colorectal cancer.
Professor Søren Hein Sindrup, MD, consultant
Clinical Institute, Odense University Hospital
Granted for 2013-2015: DKK 925,000
79. Three-dimensional dosimetry for future
therapy techniques in radiation therapy.
Peter Sandegaard Skyt, MSc
Department of Oncology, Aarhus University
Hospital
Granted for 2013-2014: DKK 1,200,000
80. Deregulation of vaults as a possible
participant to cancer development:
from basic biology to clinical trials.
Alexandra Søgaard, MSc
Study visit at Norris Comprehensive Cancer
Center, University of Southern California,
USA
Granted for 2012-2013: DKK 48,300
81. Combination of radiation therapy
and anti-angiogenesis therapy.
Brita Singers Sørensen, MSc, PhD
Study visit at BC Cancer Research Centre,
Canada
Granted for 2012-2013: DKK 61,400
*82. Identification of genetic and epigenetic
biomarkers of prostate cancer.
Karina Dalsgaard Sørensen, MSc, PhD,
associate professor
Department of Molecular Medicine,
Aarhus Hospital
Granted for 2011-2013: DKK 1,800,000
*83. Biomarkers for pancreatic cancer
stem cells – towards single-cell cancer
diagnostics.
Morten Dræby Sørensen, MSc, PhD
Centro Nacional de Investigaciones
Oncológicas, Spanish National Cancer
Research Centre, Spain
Granted for 2012-2014: DKK 1,800,000
*84. Cancer invasion and urokinase receptor
cleavage – The biomarker potential of
the cleaved forms and targeted therapy
against the cleavage mechanism.
Tine Thurison Sørensen, MSc
Finsen Laboratory, Rigshospitalet
Granted for 2012-2014: DKK 1,350,000
85. Adoptive T-cell therapy (ATCT) as
treatment of malignant haematological
disease.
Lars Vindeløv, MD, consultant
Haematology Clinic, Rigshospitalet
Granted for 2013-2015: DKK 1,500,000
Grants
*86. New points of attack for the treatment and diagnosis of cutaneous T-cell
lymphoma.
Professor Niels Feentved Ødum, MD
Department of Biology, University of
Copenhagen
Bevilget for 2010-2013: DKK 2,100,000
*87. Molecular changes in clinical bladder
cancer.
Professor Torben Falck Ørntoft, MD,
consultant
Department of Molecular Medicine
(MOMA), Skejby Hospital
Granted for 2011-2013: DKK 4,300,000
Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements:
DKK 17,466,030
* Granted before 2012 and charged to the income
statement in previous financial statements.
Basic research and epidemiological
research
88. Dystrophia myotonica and cancer.
Professor Mads Melbye, MD
Sector for Epidemiology, Statens Serum
Institut
Granted for 2013: DKK 650,000
*89. Breast cancer risk from mammographic
heterogeneity.
Professor Mads Nielsen, MSc, PhD
Department of Computer Science, University of Copenhagen
Granted for 2012-2014: DKK 1,350,000
*£90.Development of sophisticated statistical methods for examining whether the
use of mobile phones increases the risk
of brain tumours.
Joachim Schüz, MSc, PhD
Department of Biostatistics and Epidemiology, Institute of Cancer Epidemiology,
Danish Cancer Society
Granted for 2011-2013: DKK 1,350,000
*91. Stochastic modelling and analysis of
genomic data from heterogeneous
tumours, with a particular view to
determining tumour age.
Professor Carsten Wiuf, MSc, PhD
Department of Mathematical Sciences,
University of Copenhagen
Granted for 2012-2013: DKK 1,200,000
Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements:
DKK 650,000
* Granted before 2012 and charged to the income
statement in previous financial statements.
Basic, clinical and epidemiological
research
92. Cryotreatment of renal tumours –
correlation between tissue damage and
diagnostic imaging presentation.
Professor Michael Borre, consultant
Department of Urology, Aarhus University
Hospital
Granted for 2013-2015: DKK 1,500,000
Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements:
DKK 1,500,000
* Granted before 2012 and charged to the income
statement in previous financial statements.
Clinical research
93. Analysis of personal genomic rearrangements (PAGER) for controlling
bladder cancer patients.
Lars Dyrskjøt Andersen, MSc, PhD,
associate professor
Department of Clinical Medicine,
Skejby Hospital
Granted for 2013-2015: DKK 2,100,000
94. Optimising the sentinel node technique
for early diagnostics and treatment of
lymph node dissemination in melanoma.
Annette Hougaard Chakera, MSc Medicine,
PhD
Study visit at Melanoma Institute Australia
Granted for 2013-2014: DKK 99,360
*95. Molecular profiles that are predictive
for the effect of long-term antihormone therapy in patients with
ER+ breast cancer.
Professor Henrik Ditzel, MD, consultant
Dept. of Cancer and Inflammation Research,
University of Southern Denmark
Granted for 2012-2013: DKK 1,400,000
*96. Immunochemotherapy in CLL and MCL
for clinical and molecular freedom from
disease: The road to a cure?
Christian Hartmann Geisler, MD, consultant
Finsen Centre, Rigshospitalet
Granted for 2011-2013: DKK 1,200,000
97. Nausea and vomiting in advanced
cancer: epidemiology, ethiology,
significance, effect of guideline-based
therapy and two intervention studies.
Professor Mogens Grønvold, MD, PhD,
consultant
Department of Palliative Medicine,
Bispebjerg Hospital
Granted for 2013-2015: DKK 1,350,000
*98. Very early PET response-adapted
therapy of advanced stage Hodgkin lymphoma. Randomised phase III
non-inferiority study from the EORTC
lymphoma group.
Martin Hutchings, PhD, MSc Medicine
Oncology and Haematology Clinic,
Rigshospitalet
Granted for 2012-2016: DKK 250,000
*99. Chronic pain after breast cancer surgery.
Professor Henrik Kehlet, MD
Breast Surgery Clinic, Rigshospitalet
Granted for 2011-2013: DKK 1,350,000
*100. M
olecular imaging for non-invasive
tumour characteristics and tailored
cancer treatment: Translational studies
of neuroendocrine tumours.
Professor Andreas Kjær, MD, PhD, consultant
Cluster for Molecular Imaging/Clinic of
Clinical Physiology, Department of Nuclear
Medicine & PET, Rigshospitalet
Granted for 2011-2013: DKK 3,300,000
101. Chronic pain after rectal cancer
therapy. A prospective study.
Professor Søren Laurberg, MD, consultant
Surgical Department, Aarhus Hospital
Granted for 2013-2015: DKK 2,960,000
*102. A phase III trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk
endometrial cancer - ENGOT-EN2-DGCG.
Mansoor Raza Mirza, MSc Medicine,
consultant
Oncology Clinic, Rigshospitalet
Granted for 2012-2014: DKK 2,100,000
103. Prospective, randomised multi-centre
study of the value of laparoscopic
ultrasound scanning in laparoscopic
resection of colorectal cancer patients.
Professor Michael Bau Mortensen, PhD,
consultant
Surgical Department,
Odense University Hospital
Granted for 2013-2015: DKK 1,035,000
73
Danish Cancer Society | Annual Report 2012
*104. Gastrointestinal toxicity and
hepatologic complications of allogeneic
stem cell transplantation.
Klaus Gottlob Müller, MD, MSc Medicine,
consultant
Bone Marrow Transplantation Unit,
Rigshospitalet
Granted for 2012-2014: DKK 1,125,000
109. Improved tumour control and reduced
toxicity through the use of
image-guided radiation therapy
for prostate cancer.
Per Munck af Rosenschöld, PhD
Study visit at Memorial Sloan-Kettering
Cancer Center, USA
Granted for 2012: DKK 33,120
*114. Clinical trial of novel strategies for
cellular immune therapy for patients
with metastatic melanomas.
Professor Inge Marie Svane, MSc Medicine,
consultant
Department of Oncology and Haematology,
Herlev Hospital
Granted for 2012-2014: DKK 1,800,000
105. Investigator-initiated phase II studies
of irinotecan in patients with TOP1
gene amplified metastatic breast cancer
– two national DBCG studies.
Professor Dorte Lisbet Nielsen, MD
Cancer Research Centre, Herlev Hospital
Granted for 2013-2015: DKK 2,100,000
*110. Characterisation of subtypes of immune
cells for ulcerated melanomas.
Henrik Schmidt, MD, consultant doctor,
associate professor
Cancer Centre, Aarhus Hospital
Granted for 2012-2014: DKK 1,650,000
*115. Erlotinib PET scanning and measurement
of EGF receptors as predictors
of treatment response in pulmonary
cancer patients.
Boe Sandahl Sørensen, PhD, associate
professor
Department of Clinical Biochemistry,
Aarhus University Hospital
Granted for 2012-2013: DKK 900,000
*106. The importance of radiation of the
parasternal lymph nodes in women after
lymph-node surgery – positive early
breast cancer.
Birgitte Offersen, PhD, consultant doctor,
associate professor
Department of Oncology,
Aarhus University Hospital
Granted for 2012-2013: DKK 600,000
*107. Individualised, biologically adapted
radiation therapy.
Professor Jens Overgaard, MD, consultant
doctor
Department of Experimental Clinical
Oncology, Aarhus Hospital
Granted for 2011-2013: DKK 4,800,000
*108. PET probe-guided selective lymph node
staging in women with cervical cancer.
Lone Kjeld Petersen, MSc Medicine, PhD,
consultant doctor
Department of Gynaecology and
Obstetrics, Aarhus University Hospital
Granted for 2012-2013: DKK 900,000
74
111. Improvement of thiopurine/
methotrexate treatment of acute
lymphoblastic leukaemia.
Professor Kjeld Schmiegelow, consultant
doctor
Paediatric Oncology Laboratory,
Juliane Marie Centre, Rigshospitalet
Granted for 2013-2015: DKK 4,500,000
*112. PEG-asparaginase therapy in NOPHO
ALL-2008: Antibody formation,
pharmacokinetics, pharmacodynamics
and side effects.
Henrik Schrøder, MD, consultant doctor
Department of Paediatrics, Skejby Hospital
Granted for 2011-2013: DKK 1,125,000
*113. Myeloablative allogeneic
haematopoietic cell transplantation
in Denmark. Risk factors, morbidity,
mortality and long-term sequelae.
Henrik Sengeløv, MSc Medicine, PhD,
consultant doctor
Department of Haematology, Rigshospitalet
Granted for 2012-2013: DKK 460,000
*116. M
R-guided radiation therapy in locally
advanced cervical cancer: clinical results
of two international multi-centre studies.
Kari Tanderup, MSc, PhD, associate professor
Department of Oncology, Aarhus Hospital
Granted for 2012-2014: DKK 1,350,000
*117. Assessment of monitoring frequency
following radical operation in patients
with stage II and III colorectal cancer.
Peer Anders Wille-Jørgensen, MD, consultant
Surgical Department, Bispebjerg Hospital
Granted for 2010-2014: DKK 750,000
Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements:
DKK 14,177,480
*G
ranted before 2012 and charged to the income
statement in previous financial statements.
Clinical and epidemiological research
*118. Epidemiological and clinical differences
between Epstein-Barr virus positive and
negative Hodgkin’s lymphomas.
Henrik Hjalgrim, MSc Medicine, PhD,
consultant
Department of Epidemiology Research,
Statens Serum Institut
Granted for 2012-2014: DKK 1,350,000
*119. G
enomic profiling of hereditary nonpolyposis colorectal cancer; implications
for signalling pathways and phenotype.
Professor Mef Nilbert, MD, PhD
Clinical Research Centre,
Hvidovre University Hospital
Granted for 2011–2013: DKK 1,200,000
£120.Endocrine disorders and reproductive
disturbances after childhood cancer
treatment.
Jeanette Falck Winther, MSc Medicine,
senior researcher
Life after cancer, Danish Cancer Society
Research Center
Granted for 2013-2015: DKK 1,125,000
Granted by KBVU in 2012 and charged to the
income statement in the 2012 financial statements:
DKK 1,125,000
* Granted before 2012 and charged to the income
statement in previous financial statements .
Epidemiological research
£121.Medicinal products with possible
chemopreventive effects and the risk
of prostate cancer.
Søren Friis, MSc Medicine, senior researcher
Statistics, bioinformatics and registers,
Danish Cancer Society Research Center
Granted for 2013-2015: DKK 1,350,000
Grants
122. Sex hormones and the risk of
meningioma and glioma.
David Gaist, PhD, consultant doctor,
associate research professor
Department of Neurology,
Odense University Hospital
Granted for 2013: DKK 450,000
128. The importance of diagnostic variation
in Danish general practice for cancer
patient prognoses.
Professor Mogens Vestergaard, MSc
Medicine, PhD
Institute of Public Health, Aarhus University
Granted for 2013-2014: DKK 648,000
*123. The significance of hormone therapy for
the development and mortality of ovarian, colorectal and endometrial cancer.
Lina Steinrud Mørch, MSc
Clinic of Gynaecology, Juliane Marie Centre,
Rigshospitalet
Granted for 2011-2013: DKK 1,800,000
Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements:
DKK 2,943,000
* Granted before 2012 and charged to the income
statement in previous financial statements.
124. Labour market affiliation after
haematological cancer.
Professor Claus Vinther Nielsen, MSc
Medicine, PhD
Institute of Public Health, Aarhus University
Granted for 2013-2014: DKK 495,000
*125. Congenital deformities and cancer.
Professor Jørn Olsen MD, PhD
Department of Epidemiology,
Aarhus University
Granted for 2011-2013: DKK 1,200,000
*126.Psychosocial strain on patient and
partner after breast cancer. An
epidemiological investigation.
Nina Rottmann, MSc (psychology)
Institute of Public Health, University of
Southern Denmark
Granted for 2012-2013: DKK 900,000
*£127.Cancer among young Danes
– survival and heart disease as
long-term sequelae.
Kathrine Rugbjerg, MSc
Genetics and Medicine, Institute of Cancer
Epidemiology, Danish Cancer Society
Granted for 2012-2013: DKK 1,200,000
KBVU scholarships
129. The significance of B-CLL and HCMV for
the functionality of NK cells – focusing
on intracellular signalling and degranulation.
Christian Buus, medical student
Cancer immunology, Department of
Biomedicine, Aarhus University
Granted for 2012: DKK 110,000
£130.Characterisation of lysomal cystein
cathepsin B secretion in ErbB2-induced
cell invasion in malignant cancers.
Knut Kristoffer Bundgaard Clemmensen,
science student
Cell death and metabolism, Danish Cancer
Society Research Center
Granted for 2012: DKK 70,000
131. Is there an optimal timing for starting
chemotherapy after primary surgery
for ovarian cancer?
Lisbeth Lydiksen Christensen, medical
student
Department of Gynaecology and
Obstetrics, Aarhus University Hospital,
Skejby
Granted for 2012: DKK 120,000
132. The diagnostic and prognostic importance of proliferation markers in
sentinel node biopsies for malignant
melanomas.
Allan Vestergaard Danielsen, medical
student
Department of Pathology,
Aarhus University Hospital
Granted for 2012: DKK 120,000
137. A prospective study of diffusionweighted MR diagnostics of hepatic
metastases extending from colon
cancer – perspectives based on healthcare economics and patient perception.
Talie Alsadat Hadi Khadem, medical student
Gastrointestinal unit, surgical section,
Herlev Hospital
Granted for 2012: DKK 110,000
133. Leukocyte DNA-6TgN for monitoring
thiopurine-based maintenance
treatment in children with leukaemia.
Maria Schou Ebbesen, medical student
Department of Paediatrics II, Juliane Marie
Centre, Rigshospitalet
Granted for 2012: DKK 80,000
138. Characterisation of immune-regulating
cells in blood from prostate cancer
patients.
Manja Idorn, science student
Centre for Cancer Immunotherapy,
Herlev Hospital
Granted for 2012: DKK 70,000
134. Optic glioma in children and adolescents
with or without neurofibromatosis
type 1.
Charlotte Ehlers-Hansen, medical student
Paediatric Oncology Laboratory, Juliane
Marie Centre, Rigshospitalet
Granted for 2012: DKK 100,000
139. Cancer vaccination designed for
counteracting immune evasion and
immunosuppression.
Eydbjørg Gaard Joensen, medical student
Laboratory for Experimental Vaccinology,
University of Copenhagen
Granted for 2012: DKK 120,000
135. The role of Akt, Mek, c-Met and PI3K
kinase inhibitors in preventing
metastasis of tumour cells in the
triple-negative breast cancer subtype.
Jesper Dupont Ewald, medical student
Dept. of Cancer and Inflammation,
Institute of Molecular Medicine,
University of Southern Denmark
Granted for 2012: DKK 120,000
140. Immunoregulation after chemotherapy
and stem cell transplant: The
significance of interleukin-7
receptor polymorphisms.
Katrine Kielsen, medical student
Institute for Inflammatory Research,
Rigshospitalet
Granted for 2012: DKK 120,000
136. Personalised therapy for glioblastoma
patients using a new biomarker for
chemoresistance.
Sofie Hellwege, medical student
Department of Clinical Pathology,
Odense University Hospital
Granted for 2012: DKK 120,000
141. Towards personalised therapy for
glioblastoma using multiplexing of
biomarkers.
Jakob Klitkou, medical student
Department of Clinical Pathology,
Odense University Hospital
Granted for 2012: DKK 120,000
75
Danish Cancer Society | Annual Report 2012
142. Characterisation of SSX2-associated
protein complexes and their role in
chromatin regulation in cancer cells.
Stine Bjørn Kristensen, medical student
Dept. of Cancer and Inflammation Research,
Institute of Molecular Medicine,
University of Southern Denmark
Granted for 2012: DKK 110,000
143. Treatment-induced toxicity in children
with leukaemia – significance of
baseline inflammation level.
Ladan Ghulam Mohammad, medical student
Institute for Inflammatory Research,
Rigshospitalet
Granted for 2012: DKK 100,000
144. Characterisation of phenotype and
genotype of germ cell tumours in
children.
Christiane Hammershaimb Mosbech,
medical student
Department for Growth and Reproduction,
Juliane Marie Centre, Rigshospitalet
Granted for 2012: DKK 120,000
145. Trend in cervical cancer screening
results when implementing new
technologies.
Johanne Rask Møller, medical student
Institute of Public Health, Centre for
Epidemiology and Screening, IFSV,
University of Copenhagen
Granted for 2012: DKK 70,000
146. Retrospective assessment of the
quality of treatment response in acute
myeloid leukaemia and the effect on
the prognosis.
Anders Oest, medical student
Clinical Research Unit, Department of
Haematology, Aalborg Hospital
Granted for 2012: DKK 120,000
76
147. Generation and analysis of synthetic
breast cancer stem cells.
Sidsel Bering Olsen, science student
Institute of Molecuar Medicine, University
of Southern Denmark
Granted for 2012: DKK 60,000
£148.Targeted treatment of tamoxifen-
resistant breast cancer cells by inhibiting activated protein kinase signalling
pathways.
Astrid Munk Pedersen, science student
Breast Cancer Group, Danish Cancer
Society Research Center
Granted for 2012: DKK 60,000
149. Methotrexate polyglutamates in
methotrexate/6-mercaptopurine
maintenance treatment of acute
lymphoblastic leukaemia in children.
Tina Gerbek Pedersen, medical student
Paediatric Oncology Laboratory,
Rigshospitalet
Granted for 2012: DKK 120,000
150. Hereditary bowel cancer with unknown
genetic background.
Laura Aviaja Rudkjøbing, medical student
Department of Cellular and Molecular
Medicine, University of Copenhagen
Granted for 2012: DKK 100,000
151. Surgery and rehabilitation in oral
cavity cancer - database for monitoring
actions and quality and for facilitating
research.
Kirstine Rødsten, medical student
Plastic Surgery Department, Odense
University Hospital
Granted for 2012: DKK 120,000
152. A comparison of gene expression profiling of leukemic cells in bone marrow
and cerebrospinal fluid, respectively
Yagmur Sisman, medical student
Department of Paediatrics, Rigshospitalet
Granted for 2012: DKK 120,000
153. Identification of DNA methylation
biomarkers for a more correct staging
of non-small-cell lung cancer patients.
Signe Søes, medical student
Department of Biomedicine,
Aarhus University
Granted for 2012: DKK 90,000
154. Chronic inflammation and autoimmunity
in myeloid cancer: The Philadelphianegative chronic myeloproliferative
neoplasms.
Anders Lindholm Sørensen, medical student
Haematological Department,
Roskilde Hospital
Granted for 2012: DKK 120,000
155. PTLD after kidney transplant in
Western Denmark and EBV status.
Eva Futtrup Sørensen, medical student
Department of Nephrology,
Aarhus University Hospital, Skejby
Granted for 2012: DKK 120,000
156. Do guide marks on the ultrasound
transducer have an effect on blood
vessel puncture precision?
Sofie Thorn, medical student
Anaesthesiological-Intensive dept., Iresearch, Aarhus University Hospital, Skejby
Granted for 2012: DKK 110,000
157. Is ovarian cancer an infection?
– A 16S PCR investigation for bacterial
DNA in ascites fluid/tumour tissue in
ovarian cancer patients.
Julie Mie Tjørring, medical student
Department of Gynaecology and Obste­
trics, Aarhus University Hospital, Skejby
Granted for 2012: DKK 100,000
158. Expression of Polycomb and Hox genes
in CML patients: A possible marker of a
leukemic stem cell?
Rikke Tolstrup, medical student
Immune-Haematological Laboratory,
Aarhus University Hospital
Granted for 2012: DKK 120,000
159. Validation of ex vivo culture of human
breast cancer cells and the use of this
method for assessing sensitivity to BH3
mimetics.
Ea Rebekka Vinten, science student
Department of Molecular Biology and
Genetics, Aarhus University
Granted for 2012: DKK 60,000
Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements:
DKK 3,200,000
Grants from the Psychosocial Cancer
Research Committee (KPSK)
Psychosocial research
160. Preparatory grant: A comparative
anthropological study of accelerated
patient pathways: Implications for patient roles, relations and organisation.
Rikke Aarhus, MA
Diagnostics Centre, Regional Hospital
Silkeborg
Granted for 2013: DKK 56,250
161. When life hurts – a mixed-method
study of health, quality of life and
resources in 8 to 15-year-olds when a
parent suffers from cancer.
Anette Hauskov Graungaard, MSc Medicine,
PhD, post doc.
Research Unit for General Practice,
University of Copenhagen
Granted for 2013: DKK 221,000
Grants
162. Cognitive changes and existential
values and experiences in palliative
cancer patients.
Niels Viggo Hansen, MA, PhD, centre
manager
Centre for Research in Existence and
Society, University of Copenhagen
Granted for 2013: DKK 370,000
167. Daily organisation of psychosocial work
and soft relations in accelerated breast
cancer: A comparative study.
Anne Roelsgaard Obling, MA, PhD, assistant
professor
Department of Organization,
Copenhagen Business School
Granted for 2013: DKK 600,000
163. Cancer, body and self images: a visual
analysis of Danish autobiographical
cancer patient stories.
Nina Henriksen, MA, PhD, post doc.
Institute of Public Health, University of
Southern Denmark
Granted for 2013: DKK 600,000
168. Individual support for women in the
process after surgical treatment for
gynaecological cancer – a randomised
intervention study.
Professor Bent Ottesen, MD, Centre
Director
Juliane Marie Centre, Rigshospitalet
Granted for 2013: DKK 450,000
164. Establishing a disease narrative after
the patient’s first consultation with an
oncologist. An analysis of the relation
between information, narration and
healing.
Merete Demant Jakobsen, PhD, post doc.
Institute of Public Health, University of
Southern Denmark
Granted for 2013: DKK 330,000
165. Semi-outpatient treatment of patients
with acute leukaemia. Experiences of
patients and relatives – illustrated in a
rehabilitation perspective.
Lene Østergaard Jepsen, MSc Medicine
Home-care unit, Odense University Hospital
Granted for 2013: DKK 465,000
166. Philosophical dialogue in cancer
rehabilitation – cancer counselling in
a philosophical perspective.
Jeanette Bresson Ladegaard Knox, MPhil,
MA
Department of Health Services Research,
University of Copenhagen
Granted for 2013: DKK 488,000
Granted by KPSK in 2012 and charged to the income statement in the 2012 financial statements:
DKK 3,580,250
* Granted before 2012 and charged to the income
statement in previous financial statements.
KPSK preparatory grants
169. Genetic counselling for breast cancer
– patient and healthcare professional
perspectives.
Christina Vigel Mischorr-Boch, MSc (Public
Health)
Unit for Health Promotion Research,
University of Southern Denmark
Granted for 2012: DKK 187,500
Granted by KPSK in 2012 and charged to the income statement in the 2012 financial statements:
DKK 432,500 for preparatory grants.
Research grants from the Danish
Cancer Society’s Strategic
Committee (KBSU) - (terminated
June 2012)
Pool for research into social disparity
in cancer
*171. Socioeconomic status and cancer.
Selection or causal effect.
Professor Merete Osler, MSc Medicine
Department of Social Medicine, Institute of
Public Health, University of Copenhagen
Granted for 2010-2012: DKK 1,800,000
*172. Social disparity in examination and diagnosis of cancer patients – an analysis
of the importance of social factors for
the quality of cancer examination and
diagnosis and the subsequent survival.
Professor Peter Vedsted, MSc Medicine, PhD
Research Unit for General Practice,
Aarhus University
Granted for 2010-2012: DKK 1,600,000
Granted by KBSU in 2009 and charged to the income
statement in the financial statements for 2009.
Pool for research into long-term
sequelae after cancer treatment
£170Future organisation of post-treatment
follow up – developing and testing a
stratification model for the needs of
cancer patients.
Cecilie Sperling, MSc (Public Health)
Quality and Patient Safety, Danish Cancer
Society
Granted for 2012-2013: DKK 245,000
*174. L
ate side effects in patients with
testicular cancer related to chemo­
therapy and hypogonadism.
Gedske Daugaard, MD, consultant
Oncology Clinic, Rigshospitalet
Professor Bobby Zachariae, MD, MSc
(Psychology)
Psycho-oncological Research Unit,
Aarhus Hospital
Granted for 2011-2013: DKK 1,000,000
*175. P
ost-treatment sequelae after rectal
cancer.
Professor Søren Laurberg, MD, consultant
Surgical Department, Aarhus Hospital
Granted for 2010-2013: DKK 2,000,000
Granted by KBSU in 2009 and charged to the
income statement in the financial statements for
2009.
Pool for palliation research
*176. Is access to specialised palliative
care distorted and can palliative
needs among non-referred cancer
patients be met?
Mogens Grønvold, MD, PhD, associate
professor, consultant
Department of Palliative Medicine,
Bispebjerg Hospital
Granted for 2010-2013: DKK 2,500,000
Granted by KBSU in 2009 and charged to the
income statement in the financial statements for
2009.
*173. Radiation-induced long-term sequelae:
Biological background, prediction and
intervention.
Jan Alsner, MSc, PhD, associate professor
Department of Experimental Clinical Oncology, Aarhus University
Granted for 2010-2013: DKK 1,500,000
77
Danish Cancer Society | Annual Report 2012
Pool for “Live Life” – cancer prevention
effort
*177. Professor Morten Grønbæk,
MSc Medicine, MD, PhD
Centre for Intervention Research, University
of Southern Denmark
Granted for 2011-2014: DKK 31,127,821
The grant is awarded in partnership with
the Tryg Foundation.
Pool for “From Symptom to
Treatment” – optimised cancer
disease diagnostics
*178. Professor Peter Vedsted, PhD
Research Centre for Cancer Diagnosis in
Primary Care (CaP), Aarhus University
Granted for 2010-2014: DKK 15,000,000
The grant is awarded in partnership with
the Novo Nordisk Foundation.
The pool “Returning to Daily Life”
– optimised rehabilitation of cancer
patients
*179. Professor Lis Adamsen, PhD
University Hospitals’ Centre for Nursing and
Care Research, Rigshospitalet
Granted for 2011-2015: DKK 15,000,000
The grant is awarded in partnership with
the Novo Nordisk Foundation.
Strategic research initiative on
palliation
180. Activity, Cancer and Quality of Life
in your own home.
Karen la Cour, PhD, associate professor
Health, People and Society, Institute of
Public Health, University of Southern
Denmark
78
Granted for 2012-2017: DKK 3,500,000
The grant is awarded in partnership with
the Tryg Foundation.
181. “Fast track” discharge and specialised
palliative treatment in the home of the
advanced-stage cancer patient:
a randomised study.
Professor Per Sjøgren, consultant doctor,
MD
Palliative Section, Unit for acute pain
management and palliation, Rigshospitalet
Granted for 2012-2017: DKK 5,000,000
The grant is awarded in partnership with
the Tryg Foundation.
182. Security in palliative processes.
Anders Bonde Jensen, PhD, consultant
Mette Asbjørn Neergaard, PhD, staff doctor
Palliative Team, Department of Oncology,
Aarhus University Hospital
Granted for 2012-2016: DKK 4,300,000
The grant is awarded in partnership with
the Tryg Foundation.
Research professorships
*183. Clinical professorship in diagnostics and
surgical treatment of gynaecological
cancer diseases
Professor Jan Blaakær, consultant doctor,
MD
Department of Clinical Medicine,
Aarhus University
Granted for 2011-2015: DKK 5,000,000
184. Clinical professorship in surgical
application of modern imaging
diagnostics
Professor Michael Bau Mortensen
Surgical Department, Odense University
Hospital
Granted for 2012-2017: DKK 5,000,000
185. Clinical professorship in palliation
Professor Per Sjøgren, consultant doctor,
MD
Palliative Section, Unit for acute pain
management and palliation, Rigshospitalet
Granted for 2012-2017: DKK 7,500,000
186. Clinical professorship in cancertreatment sequelae
Professor Christoffer Johansen, MD, PhD,
consultant
Department of Clinical Medicine, Surgery
and Internal Medicine, University of
Copenhagen
Granted for 2013-2018: DKK 7,500,000
187. Clinical professorship in upper
gastrointestinal cancer surgery
Professor Lars Bo Svendsen, MD, consultant
Abdominal Centre, Rigshospitalet
Granted for 2012-2017: DKK 1,000,000
Grants
General overview 2012
Research grants from the Danish Cancer Society’s Scientific Committee (KVBU) and Psychosocial Cancer Research Committee (KPSK)
(DKK 1,000)
Granted in 2012 for research projects cf. overview of grants
KPSK
Basic research
Basic and clinical research
Basic and epidemiological research
Basic, clinical and epidemiological research
Clinical research
Clinical and epidemiological research
Epidemiological research
KBVU
Total
25,826
17,466
650
1,500
14,177
1,125
2,943
25,826
17,466
650
1,500
14,177
1,125
2,943
Psychosocial research
3,580
Projects, total
3,580
63,687
67,267
Granted to projects, ref. above
Granted for preparatory grants
Granted for scholarships*
Granted for trips under 1 month
3,580
433
63,687
3,200
672
67,267
433
3200
672
Granted, total
4,012
67,559
71,571
-30
-6,790
-1,096
-6,820
-1,096
3,982
59,673
63,655
Adjustment of grants
Covered by legacy income
Total consumption for the year cf. note 8 in the financial statements
3,580
Comments:
1. Postdoc and junior bursaries have been included under project grants.
2.The breakdown by specialist discipline has been based on the applicant ticking one or more of the following headings:
basic research, clinical research, epidemiology, psychosocial research and other.
* Incl. the Employers' Reimbursement Scheme (Apprentices and Trainees) (AER)
79
Danish Cancer Society | Annual Report 2012
Patients’ associations
Danish Ostomy Association
- COPA
The Patients’ Association
DBO
Chairman: Henning Granslev
Secretariat
Jyllandsgade 41
DK-4100 Ringsted
Tel.: (+45) 57 67 35 25
[email protected]
(Contact at FAP, special
subgroup:
Susanne Jacobsen
[email protected]
(Danish Breast Cancer
Organisation)
Skivevej 150
DK-9632 Møldrup
Tel. (+45) 26 82 39 29
[email protected]
Chairman: Helle Viola Haugaard
[email protected]
DALYFO
Ole Dallris
Scaniagade 14
DK-8900 Randers
Tel. (+45) 86 40 80 62
[email protected]
Danish Lymphoedema Association
Lise Petersen
Arent Hansens Vej 3, Smidstrup
DK-3250 Gilleleje
Tel. (+45) 70 22 22 10
[email protected]
Danish Association for
Laryngectomees – DLFL
Anne-Lise Steen
Lindormevej 14, Kulhuse
DK-3630 Jægerspris
Tel. (+45) 47 53 63 30
[email protected]
Office
Strandboulevarden 49, 4.
DK-2100 Copenhagen Ø
Tel. (+45) 35 25 74 24 /
(+45) 35 26 40 45
[email protected]
80
Danish Myeloma
Association
KIU – Women with
reproductive cancers
Lene Middelhede
Rosenvænget 5A
DK-8722 Hedensted
Tel. (+45) 76 74 05 44 /
(+45) 51 70 87 83
[email protected]
PROPA
Danish Prostate Cancer Association
K. B. Madsen,
Baldersvej 19
DK-4000 Roskilde
Tel. (+45) 46 37 11 09 /
(+45) 40 13 15 47
[email protected]
Secretariat:
Danish Prostate Cancer
Association PROPA
Jernbanegade 23 B
DK-4000 Roskilde
Tel. (+45) 33 12 78 28
[email protected]
Danish Association for
Children with Cancer
Jan Johnsen
Karlslunde Strandvej 56
DK-2690 Karlslunde
Tel. (+45) 20 30 09 05
[email protected]
Danish Lung Cancer
Association
Alice Skjold Braae
Virkelyst 1
DK-4420 Regstrup
Tel. (+45) 40 16 23 35
[email protected]
Danish Bladder Cancer
Association
Danish Brain Tumour
Association
The Association Netpa
Denmark
Bitten Næsted
Jægersborg Allé 29B 2. tv.
DK-2920 Charlottenlund
[email protected]
Marbækvej 8
DK-4050 Skibby
[email protected]
Danish Association of
Cancer Survivors with Late
Effects – Late Effects Group
Networks
Marianne Nord Hansen
Bringebakken 30,
DK-3500 Værløse
[email protected]
Cancer Counselling Centre in
Lyngby
Nørgaardsvej 10
DK-2800 Lyngby
(+45) 45 93 51 51
[email protected]
Proof of Life
Christian Hajdu
[email protected]
[email protected]
Børge Tamsmark
Hostrups Have 30 5 tv.
DK-1954 Frederiksberg C
Tel. (+45) 25 86 92 74
[email protected]
Melanoma network
LyLe - Danish Patients’
Association for Lymphatic
Cancer and Leukaemia
Ryesgade 27
DK-2200 Copenhagen N
Tel. (+45) 35 27 18 00
Jytte Gamby
Lundemosen 78
DK-2670 Greve
Tel. (+45) 43 90 54 50
[email protected]
[email protected]
Health centre for cancer
patients,
Counselling unit
Network for patients with
cancer of the throat and oral
cavity
Bodil Feldinger, Tel. (+45)
45 83 45 27
Niels Jessen, Tel. (+45)
48 17 59 64
c/o Centre for Cancer and Health
Nørre Alle 45
DK-2200 Copenhagen N
[email protected]
Intestinal cancer patient
network
Annelise Læssøe
Marianne de Fries Jensen
Jørgen Mathiesen
Kirsten Andersen
[email protected]
Postal address only:
Annelise Læssøe
Mariendalsvej 63B, 3.th.
DK-2000 Frederiksberg
Drivkræften
- network for young people
with cancer
Contact person: Tina Brændgaard
Tel. (+45) 35 25 74 76
[email protected]
IMPORTANT CONTACT DETAILS
Cancer Counselling Centres
Nation-wide
Cancer line
The Danish Cancer Society’s free
telephone counselling
Tel.: +45 80 30 10 30
Opening hours:
Mondays-Fridays 9 am – 9 pm
Saturdays and Sundays
noon – 5 pm
Closed on public holidays
The Capital Region of
Denmark
The cancer counselling centre
Møllestræde 6
Baghuset
DK-3400 Hillerød
Tel. (+45) 48 22 02 82
[email protected]
The cancer counselling centre
Centre for Cancer and Health
Nørre Allé 45
DK-2200 Copenhagen N
Tel. (+45) 82 20 58 05
[email protected]
The cancer counselling centre
Bornholm Hospital
Ullasvej 8
DK-3700 Rønne
Tel. (+45) 56 90 91 98
The cancer counselling centre
Nørgaardsvej 10
DK-2800 Lyngby
Tel. (+45) 45 93 51 51
[email protected]
Region Zealand
The cancer counselling centre
Hasselvænget 5
DK-4300 Holbæk
Tel. (+45) 59 44 12 22
[email protected]
The cancer counselling centre
Ringstedgade 71
DK-4700 Næstved
Tel. (+45) 70 20 26 46
[email protected]
The cancer counselling centre
Jernbanegade 16
DK-4000 Roskilde
Tel. (+45) 46 30 46 60
[email protected]
The cancer counselling centre
Volunteer Centre Lolland
Sdr. Boulevard 84, stuen
DK-4930 Maribo
Tel. (+45) 55 74 04 00
The cancer counselling centre
Søndre Allé 43 B
DK-4600 Køge
Tel. (+45) 56 63 82 29
Network café for cancer patients
and relatives
Guldborgsund Frivilligcenter
Banegårdspladsen 1A,
DK-4800 Nykøbing F
Tel. (+45) 70 20 26 46
The cancer counselling centre
Nykøbing F. Hospital
Ejegodvej 67 (bus 701)
DK-4800 Nykøbing F
Tel. (+45) 70 20 26 46
By appointment only
Cancer counselling at the
Info Shop
Lindegade 3
DK-4400 Kalundborg
Tel. (+45) 59 44 12 22
Cancer counselling at
Health Centre Odsherred
Sygehusvej 5, 1. th
DK-4500 Nykøbing Sj.
[email protected]
Appointments and information on tel.
(+45) 59 41 01 10
North Denmark Region
The cancer counselling centre
Vesterå 5
DK-9000 Aalborg
Tel. (+45) 98 10 92 11
[email protected]
New address from 26 August:
Stenstrupvej 1
DK-9000 Aalborg
Cancer counselling at the
Health Centre
Banegårdspladsen, 5, 2. sal
DK-9800 Hjørring
Tel. (+45) 98 10 92 11
First Monday of every month
9 am – 3 pm
Cancer counselling at
Dragsbækcentret
Simons Bække 37, Tilsted
DK-7700 Thisted
Information about opening hours
on tel. (+45) 98 10 92 11
Central Denmark Region
The cancer counselling centre
Overgade 17
DK-7400 Herning
Tel. (+45) 96 26 31 60
[email protected]
The cancer counselling centre
Banegårdspladsen 2. 1.
DK-8800 Viborg
Tel. (+45) 86 60 19 18
[email protected]
Hejmdal – The Cancer Patients'
House
Peter Sabroes Gade 1
DK-8000 Århus C
Tel. (+45) 86 19 88 11
[email protected]
Cancer counselling at Health
Centre West
Kirkegade 3
DK-6880 Tarm
Tel. (+45) 96 26 31 60
[email protected]
REGION OF SOUTHERN DENMARK
The cancer counselling centre
Jyllandsgade 30
DK-6700 Esbjerg
Tel. (+45) 76 11 40 40
[email protected]
The cancer counselling centre
Kulturhuset
Nygade 22
DK-7500 Holstebro
Tel. (+45) 96 26 31 60
[email protected]
The cancer counselling centre
Vesterbro 46
DK-5000 Odense C
Tel. (+45) 66 11 32 00
[email protected]
Cancer counselling at the Health
Centre
Sygehusvej 7
DK-8660 Skanderborg
Tel. (+45) 86 19 88 11
By appointment only
Cancer counselling at Randers
Health Centre
Biografgade 3
DK-8900 Randers C
Tel. (+45) 89 15 12 15
Open Mondays
10 am – 3 pm
Cancer counselling at the Health
Centre
Østergade 9, 1. sal
DK-8600 Silkeborg
Tel. (+45) 86 19 88 11
[email protected]
Cancer counselling at
Odder Volunteer Centre
Pakhuset
Banegårdsgade 5
DK-8300 Odder
Tel. (+45) 86 19 88 11
[email protected]
The cancer counselling centre
Blegbanken 3
DK-7100 Vejle
Tel. (+45) 76 40 85 90
[email protected]
The cancer counselling centre
Nørreport 4, 1.
DK-6200 Aabenraa
Tel. (+45) 74 62 51 50
[email protected]
Volunteer counselling service
Svendborg
Brogade 35 (i gården)
DK-5700 Svendborg
Tel. (+45) 23 98 06 95
Open Tuesdays 10 am – noon and
Thursdays 5 pm – 7 pm
Volunteer counselling service
– The Prevention Centre
Fredensvej 1
DK-5900 Rudkøbing
Tel. (+45) 62 51 28 90
Open Wednesdays 2 pm - 4 pm
Kolding cancer counselling
Klostergade 16
DK-6000 Kolding
Tel. (+45) 79 79 72 80
Open Mondays 9 am - 1 pm
By appointment only.
81
Danish Cancer Society | Annual Report 2012
82
Organisation
Local units
Committee of Representatives
Presidium
Central Board
Regional Committees
Executive Committee
Local Units Committee
The Danish Cancer Society’s Scientific Committee
Patient Support Committee
The Danish Cancer Society’s Strategic Committee
Prevention and Information Committee
Psychosocial Research Committee
Management
Policy and Legal Advice
Communications Department
HR
Finances & Administration
Volunteering
Fundraising
&
Membership
Patient Support
&
Community Activities
Cancer Prevention
&
Documentation
Quality
&
Patient Safety
The Danish
Cancer Society
Research Center
83
The Annual Report can be ordered from
the Danish Cancer Society by calling
(+45) 3525 7540 or downloaded from
www.cancer.dk/regnskaber
The English version is available at
www.cancer.dk/regnskaber
Danish Cancer Society
Strandboulevarden 49
DK-2100 Copenhagen
Tel. + (45) 35 25 75 00
www.cancer.dk
CVR 55 62 90 13